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 In 2011 the National Academy of Medicine identified research gaps related to 
transgender populations and suggested a research agenda that included, among other goals, 
investigating health outcomes related to transition related care. The overarching goal of this 
dissertation therefore is to add to the body of knowledge about the state of health of transgender 
individuals, including utilization of gender-affirming care, preventive care and screening 
practices for human immunodeficiency virus (HIV) and other sexually transmitted infections 
(STIs).  
This dissertation includes three manuscripts. The first is a retrospective chart review 
including 1670 transgender patients, aged 18 and up (mean age 35.57 years), at a community 
health center to examine utilization of gender-affirming procedures as well as investigate the 
prevalence of smoking and uptake of colon cancer screening compared to New York City 
benchmarks using data from the New York City Community Health Survey (NYC CHS). The 
results revealed transgender individuals had high uptake of gender affirming hormones (81.9%) 
but fewer had undergone gender-affirming surgeries (31.5%). Transgender individuals had 
almost double the rate of current cigarette smoking compared to adults aged 18 and up in the 
New York City Community Health Survey  (OR=1.92, 95% CI=1.61, 2.28) and also had 
suboptimal colon cancer screening rates compared to New Yorkers aged 50 and older (OR=0.16, 
95% CI=0.11, 0.23).  
 
 
The second paper is a scoping review of the literature to investigate postoperative 
outcomes related to vaginoplasty procedures in transgender women. One hundred and three 
articles met inclusion criteria and provided information on immediate as well as long term health 
outcomes. The review demonstrated many inconsistencies in the timing of follow-up as well as 
how outcomes were measured, but provided invaluable information on the many types of 
postoperative issues that may be seen after vaginoplasty surgery.  
Lastly, the third paper examined the prevalence of HIV and STI testing behavior and 
prevalence of HIV infection among transgender people in a community health center setting. 
This analysis demonstrated that HIV screening rates were lower than expected (55.7%) given the 
elevated HIV prevalence in the population. In the multivariate analysis the odds of HIV 
screening among transmasculine individuals was higher in those who had undergone gender 
affirming surgeries (OR=1.67, 95% CI= 1.08, 2.58), had a substance use history (OR=5.18, 95% 
CI=1.41, 18.99) and a history of genital warts (OR=4.64, 95% CI=1.24, 17.34). Among 
transfeminine individuals the odds of HIV screening were higher in those with only cisgender 
male partners (OR=2.18, 95% CI=1.52, 3.11), gender affirming surgery (OR=2.56, 95% 
CI=1.53, 4.31), substance use history (OR=2.76, 95% CI=1.23, 5.78) and genital warts 
(OR=2.69, 95% CI=1.20, 6.02). HIV prevalence was higher among transfeminine compared to 
transmasculine individuals (28.1% vs. 2.8%, p<.001). In the multivariable analysis having only 
cisgender male sex partners increased the odds of HIV infection among transmasculine 
individuals (OR=10.58, 95% CI=1.33, 84.17), while having at least a high school diploma 
reduced the odds of infection (OR=0.08, 95% CI=0.01, 0.72). Among transfeminine individuals 
increased odds of HIV-infection were seen in those who were unemployed (OR=1.7, 95% 
 
 
CI=1.1, 2.64) and those who had a history of genital warts (OR=2.54, 95% CI=1.37, 4.70). 
White individuals had a lower likelihood of HIV infection (OR=0.40, 95% CI=0.21, 0.73). 
Overall these three studies provide important information about transition-related, 
primary and preventive healthcare for transgender populations.  The findings of elevated 
cigarette smoking, underutilization of colorectal cancer screening and low HIV and STI 
screening rates occurred in this study despite the fact that transgender people were engaged in 
medical care. Clinics and other health settings that provide transgender health services should 
include robust metrics for monitoring uptake of preventive health care services and work to 
improve uptake of services when disparities are evident. 
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Chapter 1: Introduction & Overview of the Dissertation 
Transgender individuals are those whose gender identities do not align with their assigned sex at 
birth. The term transgender is considered by many to be an “umbrella” term that includes those 
with binary identities, e.g., transgender men and women as well as those who identify outside of 
the binary; gender non-binary, gender nonconforming, genderqueer, agender and bigender 
among others. The adult transgender population in the United States is estimated to be between 1 
and 1.4 million[1, 2] and includes those who have, or intend to undergo medical and/or surgical 
transition to their affirmed gender, as well as those who do not wish to undergo any type of 
gender affirming procedures.[3-5] Transition refers to the process of changing gender roles or 
expression to one that aligns with most closely with one’s gender identity. This may include 
social transition (e.g., changing names, pronouns, clothing), legal, medical and surgical 
interventions.[6, 7]  
The diverse experiences of transgender persons, whether assigned male or female at birth, 
their sexual orientation, whether they are hormone experienced or not and whether they have 
undergone transition related surgeries, present particular challenges to researchers in determining 
the impact of gender identity on health outcomes. In addition, since there are no US population-
based surveys that include gender identity as a demographic variable, it is not possible to fully 
investigate the health care needs of transgender people. The National Academy of Medicine in 
its Report “The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a 
Foundation for Better Understanding” stated that all aspects of research related to transgender-
related care needed to be prioritized.[8] 
Transgender people often experience high rates of stigma, socioeconomic and structural 
barriers to care that negatively impact healthcare utilization, increase susceptibility to human 
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immunodeficiency virus (HIV) and sexually transmitted infections (STIs) and incur missed 
opportunities for HIV and STI prevention services.[9-16]. Transgender women carry elevated 
risk factors for HIV and other STIs including high rates of sex work (often exceeding 50%), 
condomless anal receptive sex, early sexual debut and high numbers of predominately cisgender 
men sexual partners. [17-23]. Several studies reveal that the incidence and prevalence rates of 
human immunodeficiency virus (HIV) among transgender women surpass those reported among 
cisgender men who have sex with men (MSM).[19, 24-30] The rates of HIV in the USA are even 
more concerning among transgender women of color, reaching prevalence in some studies of 
over 50%.[19, 24, 31] Despite an increase in research conducted in transgender populations over 
the last decade, the majority of these studies have been small non-random surveys using 
convenience samples with a focus on HIV and STI risk [27, 32, 33] Additionally, most studies 
have examined risk among transgender women while only a few have examined HIV in 
transgender men, despite the fact that transgender men often have HIV risk factors such as 
engaging in sex work, condomless sex with cisgender men and low rates of STI screening. [15, 
34-37] There has also not been risk stratification among transgender populations, e.g., examining 
the HIV risk for transgender people who have sex with cisgender women vs. cisgender men.  
There are no large-scale population-based studies and consequently few data on general 
health issues that affect the transgender population at large, such as rates of obesity, tobacco use, 
cardiovascular disease and cancer.[8, 33] In addition, there are few data on the community’s 
utilization of preventive health services, such as screenings for cancer and diabetes, although 
data exist that transgender persons are less likely to undergo preventive health screenings or to 
be aware of their HIV status, despite being among the highest risk groups.[19, 32, 33, 38-40]  
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Transgender women who receive gender affirming hormone therapy (GAHT) often use 
the same types of estrogens as postmenopausal women whereas transgender men use testosterone 
preparations that are dosed similarly to those used for the treatment of cisgender men with 
hypogonadism.[41] Research on the mental health effects of GAHT has found that transgender 
people experience improvements in psychosocial functioning and quality of life and experience 
lower rates of anxiety and depression.[42-44] Research on the medical outcomes of GAHT have 
focused mainly on investigating metabolic effects and adverse outcomes, such as dyslipidemias, 
venous thromboembolism, bone health, cardiovascular and cancer risk.[6, 41, 45-48]. There is 
emerging evidence that receipt of GAHT may mediate the effects of transgender discrimination, 
leading to improved rates of viral suppression among transgender women living with HIV.[49] 
There have been no studies examining the indirect effects of GAHT on primary care parameters, 
e.g., whether access to hormones is associated with uptake of preventive care, such as 
improvements in STI, HIV or cancer screenings or reductions in unhealthy behaviors such as 
tobacco or substance use. Therefore, the overarching goal of this dissertation is to add to the 
body of knowledge about the state of health of transgender individuals. 
1.1 Utilization of Gender Affirming Care and Preventive Care by Transgender 
Individuals 
The first specific aim of this dissertation is to describe the utilization of transition (GAHT and 
gender affirming surgery), preventive care (colonoscopy) and health behaviors (tobacco use) by 
gender identity among transgender patients at a New York City Community Health Center 
(Chapter 2). The hypothesis is that uptake of preventive health services (colon cancer screening) 
by transgender clients attending a New York City Health Center is lower than that reported for 
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cisgender populations in New York City and that cigarette smoking rates will be higher among 
transgender compared with cisgender population.  
Rationale: Few studies have examined rates of uptake of preventive health services among 
transgender clients, since gender identity has not been included in the majority of national health 
surveys. As described above, the identification of transgender persons is challenging for 
researchers as there is considerable diversity both in terms of gender identity as well us use of 
gender affirming care and this diversity is likely to influence utilization of healthcare services. 
This study was designed to address gaps in knowledge by comparing the uptake of preventive 
health services between transgender women and transgender men clients compared to 
benchmarks from the 2010 New York City Community Health Survey. Colon cancer screening 
was chosen to examine cancer screening rates as all people ages 50 and over, whatever their birth 
sex, surgery or hormone status, should still follow standard colon cancer screening guidelines. 
1.2 A Scoping Review of Vaginoplasty Surgery Outcomes 
The second specific aim is to summarize what has been published about genital surgery 
(vaginoplasty) in transgender women, including a description of different surgical techniques, 
quality measures, postoperative complications and long-term health outcomes (Chapter 3). 
Rationale: The proportion of genital surgeries has increased over the last 2 decades in part due 
to changes in health insurance laws that now include reimbursement for gender affirming care. 
Several narrative and systematic reviews [47, 48, 50-53] have examined long-term health 
outcomes related to cross-sex hormone therapy; however, to our knowledge, although there have 
been systematic reviews of surgical techniques, short term health outcomes and a recent review 
of outcome measures,[54-57] there have been no comprehensive reviews investigating short and 
long-term health outcomes related to these surgeries for transgender women who have undergone 
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genital surgery. Aggregating existing research and identifying gaps in knowledge will be useful 
for clinicians providing primary care and surgeons, inform future research, as well as assist 
policy makers seeking to create quality measures for care of transgender people 
1.3 HIV and STI Prevalence among Transgender People 
The third specific aim is to describe the prevalence of HIV and sexually transmitted infections 
(STIs) among transgender clients attending a New York City Health Center and to investigate 
HIV and STI screening practices (Chapter 4).  
Hypothesis 1: There will be distinct differences in the prevalence of HIV and STIs between 
transgender men and transgender women  
Hypothesis 2: The gender of sex partners will have an impact on the prevalence of HIV and 
STIs in both transgender men and transgender women  
Hypothesis 3: The third hypothesis is that patients who access gender affirming care will be 
more likely to undergo screening for HIV and STIs 
Rationale: A recent systematic review and metanalysis of HIV among transgender women 
estimates the US prevalence of HIV to be 14% among transgender women with the highest 
prevalence among black (44%) and Hispanic/Latino (26%) transgender women.[24] Data also 
suggest high rates of HIV among transgender women globally.[25] The few studies of HIV 
prevalence and incidence in transgender men suggest that they have a lower prevalence of HIV 
than transgender women, approximately 2%.[24]   
There are limited data both about STI screening behaviors as well as STI prevalence 
among transgender people of all gender identities, including gender nonbinary people. Gender 
affirmation has been shown to mediate transgender-related stigma and may result in improved 
health outcomes.[49] To our knowledge, there are no data on HIV and STI screening practices or 
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prevalence of infection in transgender people who have received GAHT or undergone gender 
affirming surgeries.  
The aim of this report was therefore to examine rates of screening behaviors and 
prevalence of HIV, syphilis, Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) and 
CT infections in transgender people using retrospective chart review data from a community 
health center in New York City. 
The Importance of this Research 
Transgender people are understudied and there are large gaps in knowledge about the utilization 
of both transition-related and non-transition primary health care. It is hypothesized that 
structural, interpersonal and individual level stigma adversely affect health outcomes for 
transgender people and that this relationship may be modified by access to gender affirming care 
(Figure 1). This dissertation provides important information on the uptake of gender-affirming 
care, both hormones and surgeries by transgender people and the relationship to primary care 
outcomes. This paper also highlights that transition-specific health outcomes, through the 
example of vaginoplasty surgery, have not been well studied and that outcome measures are not 
standardized. Preventive care utilization is often used as a health care quality metric however 
comparing data between transgender and cisgender populations is hindered by the fact that many 
healthcare quality indicators are based on birth sex (e.g., breast or cervical cancer screening), and 
may not be appropriate for those who have undergone surgeries or taken hormones. The 
dissertation provides meaningful comparisons of preventive care between cisgender and 
transgender populations using health indicators that can be applied independent of gender 
identity (colorectal cancer screening, HIV and STI screening, smoking). These identified gaps in 
measurement will hopefully lead to a new research agenda to identify and develop standardized 
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and appropriate health outcome measures that can be used to assess interventions in transgender 
populations. 
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Chapter 2: Utilization of Gender Affirming Care and Preventive 
Care by Transgender Individuals 
2.1 Introduction 
Transgender people have a gender identity that differs from the sex that they were assigned at 
birth.[6, 58] A recent meta-regression analysis indicated that approximately one million adults in 
the United States (US) aged 18 years and older  (0.4% of the adult population) identify as 
transgender[1] with an estimated 25 million adults worldwide. A higher proportion of youth, 
almost 2% of high school students, identify as transgender.[59]  
Transgender women (“trans women” or “women of transgender experience”) are women 
who were assigned male at birth (i.e., born with male anatomy).  Transgender men (“trans men” 
or “men of transgender experience”) are men who were assigned female at birth (i.e., born with 
female anatomy). Some individuals may identify outside the gender binary of male or female or 
move back and forth among different gender identities and use terms such as gender nonbinary, 
genderqueer, gender nonconforming or gender fluid to describe themselves. Agender or null-
gender persons do not identify with having any gender. The terms cisgender is used to describe 
persons who identify with their assigned sex at birth. Although there are no US population-based 
estimates for the prevalence of gender nonbinary people, approximately 35% of the 27,715 
respondents of the 2015 U.S. Transgender Survey (USTS) identified as gender nonbinary.[60] 
Some transgender individuals may seek medical (hormonal and/or surgical) interventions 
in addition to social or legal changes, e.g., changing their name and/or gender marker.[6]  
Transgender women who receive gender affirming hormone therapy (GAHT) often use 
the same types of estrogens as postmenopausal women in addition to an androgen blocker, such 
as spironolactone, whereas transgender men use testosterone preparations that are dosed 
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similarly to preparations used for the treatment of cisgender men with hypogonadism.[41] 
Research on the psychosocial effects of gender affirming hormone therapy (GAHT) shows that 
transgender people experience improvements in psychosocial functioning and quality of life and 
experience lower rates of anxiety and depression.[42-44] Research on the medical outcomes of 
GAHT have focused mainly on investigating metabolic effects and adverse outcomes, such as 
dyslipidemias, venous thromboembolism, bone health, cardiovascular and cancer risk.[6, 41, 45-
48].   
Despite an increase in the number of publications focusing on transgender persons over 
the last decade, most of these have focused on mental health, e.g., anxiety, depression and other 
mood disorders, HIV and STIs (predominately among those assigned male at birth), substance 
use, violence, stigma and discrimination.[61] Studies have frequently been small cross-sectional 
studies, e.g., in gender clinics or STI clinics, or community-based studies using convenience 
sampling methods. Due to the lack of gender identity (separate from birth assigned sex) being a 
demographic variable measured in national surveys, there are no large-scale population-based 
studies and consequently few data on general health issues that affect the transgender population 
at large, such as rates of obesity, tobacco use, cardiovascular disease and cancer.[8, 33, 61] In 
addition, there are few data on the community’s utilization of preventive health services, such as 
screenings for cancer and diabetes, although data exist that transgender persons are less likely to 
undergo preventive health screenings or to be aware of their HIV status, despite being among the 
highest risk groups.[19, 32, 33, 38-40] One study examined cancer screening among transgender 
people using data from the 2014-2016 Behavior Risk Factor Surveillance System surveys. This 
revealed that transgender women were less likely to undergo mammography compared to 
cisgender women and transgender men were less likely to have ever had a cervical pap test. The 
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authors also examined colorectal cancer screening. In the multivariable analysis gender 
nonbinary individuals had a lower rate of ever having a colonoscopy or sigmoidoscopy and 
transgender men had a statistically significant higher rate of being up to date with colorectal 
cancer screening than cisgender individuals.[40] There have been no studies examining the 
indirect effects of GAHT on primary care parameters, e.g., whether access to hormones is 
associated with uptake of preventive care, such as improvements in STI, HIV or cancer 
screenings or reductions in unhealthy behaviors such as tobacco or substance use. 
The aim of this report therefore is to examine rates of utilization of gender affirming care 
as well as health indicators among transgender people. It was decided to examine colon cancer 
screening as the recommendations do not differ by assigned birth sex, unlike other screening 
recommendations, such as breast or cervical cancer, that may need to be modified in transgender 
people who have accessed hormones or surgery. The second health factor investigated was 
smoking status. The data were obtained using retrospective chart review data from a community 
health center in New York City. In order to make a comparison of health behaviors, the 
prevalence of screening practices and tobacco use will be compared to New York City 
benchmarks. 
2.2 Methodology 
Sample and Setting   
A retrospective chart review of transgender and gender nonbinary patients was conducted 
between 1/1/2009 and 12/31/2010 using data from the electronic health records at Callen Lorde 
Community Health Center (CLCHC). This project was initiated to answer questions about the 
state of health of transgender patients age ≥ 18 years including uptake of preventive health 
services that would frame the direction of future prevention efforts. CLCHC is a health center in 
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New York City that provides primary care, transgender health, sexual health and HIV services to 
the lesbian, gay, bisexual and transgender communities and people living with HIV. CLCHC has 
been providing transgender primary care services for over a decade. The Center is located across 
3 clinical sites and 2 administrative sites in lower Manhattan and the Bronx. Its main clinical site 
is a 27,000-square foot, six-story building that is an ADA-compliant, fully licensed New York 
State Department of Health Article 28 Diagnostic and Treatment Center. In 2002, CLCHC was 
also designated a Federally Qualified Health Center (FQHC) by the U.S. Department of Health 
and Human Services’ Bureau of Primary Health Care. In 2018 CLCHC provided gender 
affirming services to 17,018 individuals, including 4,000 transgender and gender nonbinary 
individuals, making this the largest clinic cohort of transgender people in North America. In 
2010, CLCHC had 14,961 unique patients and approximately 1700 of these identified as 
transgender and gender nonbinary.  
Although patient-related data cannot substitute for population level data, the CLCHC, as 
a Federally Qualified Health Center provides treatment care and support regardless of ability to 
pay, thereby attracting a clinic population that is racially, ethnically and economically diverse.  
Data Extraction 
At the time of the study the CLCHC recorded data regarding birth sex and gender identity in 
several different locations, including paper registration forms and in the electronic health record. 
Established patients had the sex listed on their insurance card (frequently birth sex) at 
registration and in the electronic health record. There was a specific question in a social history 
template within the electronic health record that asked current gender identity, Figure 1. This 
included a dropdown list (male, female, trans male/FTM, trans female/MTF) and also allowed 
medical providers to write in a gender not listed. Figure 1. The Center’s electronic health record 
 12  
 
also included a preferred name field that permitted people to provide another name in addition to 
their legal name. Patients seeking gender affirming care were given ICD-9 codes for 259.9 
(unspecified endocrine disorder). 
 








Patient-level data obtained from the electronic medical records at CLCHC were used to 
investigate the demographic profile of transgender persons seeking care, to evaluate utilization of 
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health services, including preventive health services and to determine if these differed by age, 
race, ethnicity, use of GAHT and other demographic factors. 
Subjects were registered patients 18 years of age or older treated at the CLCHC between 1/12009 
and 12/31/2010.  
Inclusion Criteria: 
1. A patient treated at the health center between 1/1/2009 and 12/31/2010 
2. Identified as transgender 
3. Age 18 or older 
4. No subject to be excluded from the study on the basis of gender, racial or ethnic origin.   
Patient charts meeting any of these criteria were pulled for chart review to determine eligibility 
of transgender status: 
• A person with a diagnosis code of 259.9 (unspecified endocrine disorder). At CLCHC 
transgender clients were usually assigned an ICD-9 code of 259.9 instead of group 30 codes (e.g. 
302.85 – “gender identity disorder in adolescents or adults” or 302.5 codes “transsexualism”). 
• A person with two first names recorded on the registration screen. Patient first names are 
found in 2 fields, one for “preferred” and another for “legal” name. Discordance in the names 
may signify someone who is in the process of transition who has not changed their name legally. 
• A person self-identified as transgender, transsexual, genderqueer, queer, gender 
nonconforming or other gender non-conforming term in the electronic health record social 
history template that patients had disclosed to their medical provider.  
• A person with gender male or female in the social history template that differs from the 
gender listed in the registration template. A transgender person often has identity documents that 
have discordant genders, for example, medical insurance of a transgender male may still be 
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marked “female” which is the legal gender placed on the registration form. Discordance in these 
2 records may signify that someone is transgender. 
• A person with gender documented as female on the registration template who receives 
testosterone therapy. Although testosterone is prescribed for some medical conditions in women, 
the majority of clients receiving testosterone with legal gender marker female, will be 
transgender men. 
• A person with gender documented as male on the registration template who receives 
estrogen therapy.  
• A person who receives spironolactone therapy. Spironolactone is a common androgen 
blocker used in feminizing hormone regimens. 
 
Due to the inherent difficulty with identifying transgender patients, an initial data run was 
conducted to identify transgender subjects using several criteria as outlined above. All patients 
that met at least one of the above criteria were deemed eligible for an in-depth chart review to 
determine gender identity. The charts were examined to determine whether each patient was 
transgender, i.e. identified as a gender other than their sex assigned at birth. This included a 
review of the medical history, physical examination and medication templates as well as reading 
through free text in the chart notes. The goal was to find criteria that would be sensitive for 
transgender identity.  Factors used to maximize sensitivity for identifying transgender individuals 
included ICD codes, discordance between birth sex and affirmed gender identity, discordance 
between name and recorded gender and prescriptions for gender affirming hormone therapy. 
Variables collected also included: age, race, birth sex, current gender identity, gender of sexual 
partners, housing status, insurance, height, weight, blood pressure, cholesterol levels, presence of 
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diabetes, silicone use, tobacco use, alcohol use, sexually transmitted infections (gonorrhea, 
chlamydia, syphilis, HIV), gender confirming surgeries and hormone therapy.   
Data Quality Assurance 
• The study’s principal investigator (PI) trained one chart reviewer using a standard chart 
review protocol. Both the trainer and trainee independently reviewed the same charts over a three 
day period (~20). After each chart was reviewed by both, discrepancies were noted and the chart 
re-reviewed to adjudicate discrepancies.   
• Both the PI and the chart reviewer reviewed charts to determine eligibility into the study. 
• The majority of data were entered by the chart reviewer, with random spot checks by the 
PI. 
• We statistically examined the data with frequency distributions of outcome 
variables/endpoints to identify outliers or questionable data points that may have represented 
data errors.   
After the first data run, the charts were examined by the PI and the trained chart reviewer 
to determine if the clients were transgender and prevent misclassification in the database. 
Information was collected and stored in a password-protected electronic database.  The chart 
numbers were de-identified to protect patient confidentiality. There was no key or linking list to 
allow matching of patient or patient identifiers to the database.  
This retrospective chart review (termed the Transgender Data Project on the application) 
obtained IRB approval from The Clinical Directors Network’s institutional review board on 
September 7, 2011.  
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Comparison with the New York City Community Health Survey 
Every year the New York City Department of Health and Mental Hygiene conducts a community 
health survey (NYC CHS) of non-institutionalized adults who are 18 years of age and older to 
better understand health care factors as well as risk behaviors. Respondents must have a cellular 
or landline telephone. The NYC CHS conducted a survey in 2011[62]  that corresponded to the 
dates that patient data were collected from the CLCHC. The NYC CHS used a stratified random 
sample in order to obtain citywide estimates. The sampling frame for this study was derived from 
a list of telephone numbers provided to the DOHMH by a commercial vendor. Only one adult 
from a given household completed the 25-minute survey. The NYC CHS utilized a computer-
assisted telephone interviewing system that was available in multiple languages. The survey 
covered a broad range of topics including demographics, socio-economic status, health insurance 
status, smoking and alcohol use, height, weight, sexual behavior, sexual identity, HIV testing and 
determined prevalence of a wide variety of chronic medical conditions, such as diabetes, 
hyperlipidemia and hypertension as well as uptake of preventive services, including 
colonoscopy, mammography and cervical Papanicolaou tests. All of the information obtained 
was based on self-report and the data were cross-sectional. The 2011 NYC CHS contained 
questions on sex, education, race/ethnicity, employment, age, colonoscopy ever, HIV test ever 
and smoking. In 2011 a total of 8,792 individuals participated in the NYC CHS with a response 
rate of 40%. Additional details available at: https://www1.nyc.gov/site/doh/data/data-
sets/community-health-survey.page 
The survey data from the NYC CHS are freely available on the survey website and can be 
downloaded for public use. The survey was felt to provide a good comparison to the CLCHC 
transgender patient data because CLCHC patients form a subset of New York City residents, non-
 17  
 
institutionalized adults age 18 and over and the year of the survey (2011) matched the time frame that 
the chart review occurred. In addition, the NYC CHS captured many of the same variables that were 
collected during the chart review, such as age, race/ethnicity, insurance status, education, employment, 
tobacco use, colorectal cancer screening with colonoscopy and HIV screening.  
Health indicators needed to be identified that would provide a meaningful comparison between 
the CLCHC transgender patients and the predominately cisgender NYC CHS survey participants. 
Many preventive health screenings are based on birth sex, e.g., cervical and breast cancer screening 
and osteoporosis screening, and therefore could not be compared, since transgender people may have 
undergone surgeries or taken hormones that directly impact on the need for screening. It was decided 
therefore to examine colorectal cancer screening rates in those over 50 years, as well as examine 
cigarette smoking rates since these do not change in people who have undergone surgeries or taken 
GAHT. 
Once difference between the NYC CHS participants and the CLCHC patients was that the 
patients were engaged in care which might positively influence uptake of preventive screenings. What 
was unique about the 2011 NYC CHS is that it included a question about whether participants had 
“one person or more than one person you think of as your personal doctor or health care provider.” 
NYC CHS participants who answered in the affirmative were therefore included in a merged data set 
to allow for better comparison between gender identity and health outcomes, since both survey 
participants and patients would be engaged in care. 
The following questions and answers were mapped to similar questions in the data set of 
transgender patients. In addition, colonoscopy rates for eligible clients (age 50+) was compared 
between the two populations stratified by birth sex. The potential confounders, such as age, 
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education, insurance status, race and ethnicity were available in both datasets.  Variables from the 
NYC CHS used in the analyses are listed in Table 1.
 





Table 1: Variables used from the New York City Community Health Survey 
Recoded 
Variable  
Question  Source  Responses  Recoding into new 
Variables 
pcp11  Do you have one person or more than one person 
you think of as your personal doctor or health 
care provider?  
Q2.3  1=Yes  
2=No  





sex Because it is sometimes difficult determine over 
the phone, I am asked to confirm with everyone. 





Birth Sex    Gender 
identity 
1= Male      
Cisgender male 









1=Less than HS 





Less than High 
School = 1 
High or more = 2 
Smoker Have you smoked at least 100 cigarettes in your 
entire life? 
Do you now smoke cigarettes every day, some 

















Colonoscopy is an exam in which a tube is 
inserted in the rectum to view the bowel for 
signs of cancer or other health problems. Have 



































Are you Hispanic or Latino? Some people, aside 
from being Hispanic, also consider themselves to 
be a member of a racial group. Which one or 





































agegroup What is your age? We are only asking this 
information to make sure we have talked to 
enough people in each age group. Can you just 






































1=Less than HS 





1=Less than HS 







Do you have any kind of health insurance 
coverage, including private health insurance, 
prepaid plans such as H-M-Os, or government 
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Analysis 
Analyzing Transgender Data with Multiple Gender Categories 
In order to analyze these data the gender identities were first collapsed into 4 main categories 
based on assigned sex at birth. Transgender individuals assigned male at birth who identified as 
transgender female/woman, MTF, transsexual and transgender individuals were placed in a 
binary gender identity called transgender women. This category also included transgender 
women who chose “female” as their sex assigned at birth. Nonbinary identities assigned male at 
birth (AMAB-NB) included gender nonconforming, genderqueer and those gender identities 
listed as “other” except for “woman of trans experience” which was included in the transgender 
women category. For individuals assigned male at birth with an apparent binary gender identity 
the category was called transgender men and included transgender male/man, FTM, transsexual 
and transgender individuals. Nonbinary identities assigned female at birth (AFAB-NB) included 
the identities listed as gender nonconforming, genderqueer and those listed as “other”. We have 
also used the term “transmasculine” to include all people assigned male at birth (transgender men 
and AFAB-NB) and transfeminine to include all people assigned male at birth (transgender 
women and AMAB-NB), Table 2. There were 44 transgender individuals (29 transgender men 
and 15 transgender women) who chose their affirmed gender rather than sex assigned as birth on 
the original birth certificate when asked to answer this question. In the analyses they are included 
under the assigned sex on their original birth certificate. 
 Statistics 
The prevalence of the health conditions and screenings were calculated overall and also 
separately by transfeminine/transmasculine identity and age category. Pearson chi-square tests or 
Fisher’s exact tests for cell counts ≤5 were used to compare categorical variables by birth sex 
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and independent sample t-test to compare continuous variables by birth sex. To compare the 
rates of cigarette smoking and colon cancer screening with the NYC population, the transgender 
data were merged with a publicly available data set from the 2011 NYC CHS. Only survey 
participants who were engaged in care were included in the analyses. All respondents and 
transgender people were analyzed according to birth sex, with an additional variable added for 
transgender status (1= transgender, 0= not transgender). An assumption was made that over 
99.5% of the NYC CHS were cisgender based on available population statistics. Multivariable 
logistic regression models were used to assess the associations among gender identity and 
tobacco and colon cancer screening. All p-values are two-tailed at a significance level of 5%. 
Analyses were performed using IBM SPSS Statistics for Windows, Version 26.0 
 





male at birth 
Transgender man Non-Binary assigned 



















*Based on the assigned sex on the original birth certificate. † woman of trans experience was 
placed in the binary category. 
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2.3 Results 
Using the criteria noted above, 3,197 records were initially retrieved. These were reviewed 
manually and 1,670 of the records were identified as transgender patients. In 2010, CLCHC had 
14,961 unique patients, therefore the prevalence of transgender patients at the center was 11.2%.   
Gender Identities in the Electronic Health Record 
The 1,670 transgender people included 1,105 who documented their assigned sex at birth as 
male, 565 who documented their assigned sex at birth as female. Two intersex individuals were 
not included in subsequent analyses. There was considerable diversity in how clients identified 
their gender identity.  Gender identities listed at least 4 times, including male, female and 
transgender male, transgender female, MTF (female-to-male), FTM (female-to-male), 
transsexual, GNC (gender nonconforming) and genderqueer are included in Table 3.  An 
additional 42 (2.5%) patients identified as another gender such as multi-spirit, two-spirit, unicorn 
and androgynous, these identities were chosen 3 times or less and are summarized in Table 4. 
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Table 3: Documentation of gender identity in electronic health records  
 Assigned Sex at Birth 
 Male Female Total 
Gender Identity n % n % n % 
Male 2 0.2 88 15.3 90 5.4 
Female 113 10.3 0 0 113 6.8 
Genderqueer 2 0.2 24 4.2 26 1.6 
FTM* 0 0 14 2.4 14 0.8 
MTF* 13 1.2 0 0 13 0.8 
Transgender 13 1.2 11 1.9 24 1.4 
Transgender woman 885 81.0 0 0 885 53.0 
Transgender man 0 0 413 71.6 413 24.7 
Transsexual 39 3.6 7 1.2 46 2.8 
GNC* 1 0.1 3 0.5 4 0.2 
Other 25 2.3 17 2.9 42 2.5 
Total 1093 100 577 100 1670 100 
*MTF (male to female), FTM (female to male), GNC (gender nonconforming) 
 
Table 4: Other Gender Identities 
Three or fewer persons chose one of these terms to describe their gender identity:  
Ambiguous, andro, androgynous, boy, butch trans, dual-spirit, effeminate, female/drag, 
feminine aura, feminine male, femme butch queen, gender evolving, gender neutral, 
genderqueer, lady, male-gender, male id-butch, none, nothing, no gender, no label, no term, 
not well described, prefer not to say, queer, questioning, tomboy girl, trans identified, trans not 
stated, trans/two spirit, transvestite, two-spirit, undecided, undefined, unicorn, unidentified, 
unknown, unspecified, unsure, variant, whatever, woman of trans experience 
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Demographics 
The mean age of the sample was 35.57 years, SD 11.54, range 18.0-85.1). Transfeminine and 
transmasculine individuals differed significantly by age, race, education and employment. 
Transfeminine individuals were on average 37.4 years old (range: 18.0-85.1) while 
transmasculine individuals were approximately 5 years younger, p<.001. Transmasculine 
individuals were predominately white (55.0%) whereas transfeminine individuals were more 
likely to be people of color (71.3%), p<.001. The two populations differed in other ways, 
including rates of education. Transmasculine individuals were more highly educated with 95.1% 
having at least a high school diploma, 33.1% having a 4-year college degree and 18.7% holding 
a graduate degree, compared to 84.1%, 17.7% and 6.6% among transfeminine individuals 
respectively, p<0.001. Unemployment rates were much higher among transfeminine people – 
28.7% among transmasculine and 46.4% among transfeminine people, p<.001. While both 
groups had similar rates of being uninsured (12.2% and 14.1%, p=.323) the types of insurance 
were different with transmasculine individuals twice as likely to have private insurance, p<.001. 
Transmasculine individuals were more likely to report stable housing vs. unstable/homeless 
96.6% vs. 93.5%, p=.012 Table 5.
    












t-test (df) p-value (2-
sided) 











Race/Ethnicity % n=496 % n=942 % n=1438 χ2 (df) <.001 
Hispanic 11.7 58 29.4 277 23.3 335 114.38 (4) 
White 55.0 273 28.7 270 37.8 543 
Black 13.9 69 21.3 201 18.8 270 
Asian/Pacific Islander 5.8 29 7.4 70 6.9 99 
Other 13.5 67 13.2 124 13.3 191 
Education (highest level) % n=493 % n=843 % n=1336 132.82 (4) <.001 
Less than High School 4.9 24 15.9% 134 11.8 158 
High School Diploma 11.8 58 25.3% 213 20.3 271 
Some College 31.6 156 34.5% 291 33.5 447 
Bachelors’ Degree 33.1 163 17.7% 149 23.4 312 
Graduate degree 18.7 92 6.6% 56 11.1 148 
Unemployment % n=540 % n=962 % n=1502 44.93 (1) <.001 
  28.7 155 46.4% 446 40.0 601 
Housing (stable) % n=526 % n=939 % n=1465 6.25 (1) .012 
 96.6 508 93.5% 878 94.6 1386 
    





Sex work % n=577 % n=1093 % n=1670 29.94 (1) <.001 
 0.3 2 5.5% 60 3.7 62 
Insurance % n=599 % n=944 % n=1443 147.60 (2) <.001 
Uninsured 12.2 61 14.1 133 13.4 194 
Private 60.5 302 28.6 270 39.6 572 
Public 27.3 136 57.3 541 46.9 677 
Substance use disorder % n=577 % n=1093 % n=1670 6.74 (1) .009 
 3.1 18 6.0 66 5.0 84 
Tobacco use % n=537 % n=979 % n=1516 6.03 (2) .049 
Never smoker 53.8 289 55.0 538 54.6 827 
 Current smoker 25.3 136 28.9 283 27.6 419 
Ex-smoker 20.9 112 16.1 158 17.8 270 
Colonoscopy (≥50 years) % n=38 % n=177 % n=215 1.78 (1) .183 
 15.8 6 26.0 46 24.2 52   
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Uptake of Gender-affirming Care 
The majority (82%) of transgender people had accessed hormones, either testosterone for 
transmasculine or estrogens for transfeminine individuals. Transfeminine individuals were more 
likely to have accessed hormones, 83.5% vs. 78.9%, p=.018. Transmasculine surgical 
interventions included mastectomy, phalloplasty, metoidioplasty, hysterectomy and 
oophorectomy. Transfeminine surgeries included breast augmentation, orchiectomy, 
vaginoplasty and facial feminization surgery. Although these surgeries could not be directly 
compared, a variable for “any surgery” was created. Transmasculine individuals were more 
likely to undergo at least one gender affirming surgery (41.6% vs. 26.2%, p<.001) however 
transfeminine individuals were more likely to have received either hormones or surgery i.e., “any 
gender affirming intervention” (86% vs. 82%, p=.030). Table 6.  
  
     
 
 












Interventions N % Interventions N % χ2 (df) p-value 
Hormones 
(testosterone) 
455 78.9% Hormones 
(estrogens) 
913  83.5% 5.57 (1) .018 
Mastectomy 227 39.3% Breast augmentation 167 15.3% - - 
Metoidioplasty 6  1.0% Orchiectomy 115  10.5% - - 
Phalloplasty 4  0.7% Vaginoplasty 103  9.4% - - 
Hysterectomy 53  9.2% Facial feminization surgery 98  9% - - 
Oophorectomy 45 7.8%    - - 
Any surgery  240  41.6% Any surgery 286  26.2% 41.66 (1) <.001 
Any gender affirming 
intervention 
(hormones/surgery) 
473  82% Any gender affirming 
intervention 
(hormones/surgery) 
940 86% 4.70 (1) .030 
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Colonoscopy and Cigarette Smoking among Transgender People (Table 5) 
The rate of colonoscopy was evaluated for the 215 people who were aged 50 and over and therefore 
eligible for this procedure. Approximately 15.8% of transfeminine individuals had ever undergone a 
colonoscopy compared with 26% of transmasculine individuals, p=.183. 
The rates of never smokers were similar by gender identity with 53.8% of transmasculine 
individuals and 55% of transfeminine individuals stating they had never smoked, p=.67. The rate 
of current smokers was higher among transfeminine individuals, 28.9% vs. 25.3% although this 
was not statistically significant p=.136 
Comparisons with the New York City Community Health Survey data 
The 2011 NYC CHS had 8,792 respondents of whom 7779 stated that they had one or more 
primary care providers. These 7779 “engaged in care” respondents were merged into the 
transgender data base.   
Transgender people were younger than the individuals in the NYC CHS. The proportion 
of transgender individuals ≥50 years was 12.9% vs. 59.1%, p<.001. Transgender individuals 
were more likely to be people of color (62.2% vs. 53.9%, p<.001), unemployed (40.0% vs. 12%, 
p<.001) and uninsured (13.45 vs. 7.4%, p<.001). Similar proportions of transgender and NYC 
CHS respondents had received a high school diploma (88.2% vs. 86.6%, p=.115), Table 7 
 
      
 
 












t-test (df) p-value 
(2-sided) 
Age Group % n=1670 % n=7761 % n=9431 χ2 (df) <.001 
18-24 18.0 301 4.4 345 6.8 646 1654.81 (4) 
25-29 22.0 367 4.8 376 7.9 743 
30-44 38.9 649 21.2 1648 24.4 2297 
45-64 19.8 331 40.2 3120 36.6 3451 
65+ 1.3 22 29.3 2272 24.4 2294 
50+ 12.9 215 59.1 4585 51.38 4800  <.001 
Race/Ethnicity % n=1438 % n=7779 % n= χ2 (df) <.001 
Hispanic 23.3 335 22.8 1771 22.8 2106 470.30 (4) 
White 37.8 543 46.1 3583 44.8 4126 
Black 18.8 270 21.7 1688 21.2 1958 
Asian/Pacific Islander 6.9 99 7.7 597 7.6 696 
Other 13.3 191 1.8 140 3.6 331 
People of color 62.2 895 53.9 4196 55.2 5091 33.81 (1) <.001 
Unemployment % n=1502 % n=4620 % n=6122 582.76 (1) <.001 
  40.0 601 12.0 553 18.9 1154 
      
 
 












t-test (df) p-value 
(2-sided) 
Education (highest) % n=1336 % n=7735 % n=9071 119.51 (3) <.001 
Less than High School 11.8 158 13.4 1037 13.2 1195 
High School Diploma 20.3 271 21.1 1633 21.0 1904 
Some College 33.5 447 20.4 1577 22.3 2024 
Bachelors’ Degree 34.4 460 45.1 3488 43.5 3498 
≥High school Diploma 88.2 1178 86.6 6698 86.8 7876 2.49 (1) .115 
Insurance % n=1443 % n=7756 % n=9199 89.78 <.001 
Uninsured 13.4 194 6.3 490 7.4 684 
Tobacco use % n=1516  n=7731  n=9247 210.89 (2) <.001 
Never smoker 54.6 827 59.1 4566 58.3 5393 
 Current smoker 27.6 419 27.5 2123 25.9 2393 
Ex-smoker 17.8 270 13.5 1042 15.8 1461 
Current smoker 27.6 419 13.5 1042 15.8 1461 191.04 (1) <.001 
HIV Test Ever % n=1613 % n=7499 % n=9112 2.86 (1) .091 
 55.7 898 58 7499 57.6 5245 
Colonoscopy (age ≥50) % n=215 % n= % n= 286.00 (1) <.001 
 24.2 52 76.1 3489 73.8 3581 
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Colonoscopy rates in the NYC CHS for adults 50 and over were high, 76.8% of cisgender men 
and 75.7% of cisgender women had ever had a colonoscopy compared to 15.8% among transfeminine and 
26% of transmasculine people, p<.001. The rate of ever having a colonoscopy was twice as likely in the 
age group 65+ compared to 50-64 (OR=1.98, 95% CI=1.73, 2.26) and among those who were insured 
(OR=2.1, 95% CI=1.60, 2.74). Female birth sex was associated with small (15%) increase in the rate of 
screening (OR=1.15, 95% CI=1.01, 1.31). The strongest association with ever having had a colonoscopy 
was transgender status, with transgender individuals being 90% less likely to have ever had a screening 
compared with cisgender individuals (OR=0.1, 95% CI= 0.07, 0.14). There was no association between 
race and ethnicity (dichotomized as white/nonwhite). Age, birth sex, transgender status, employment and 
insurance were included in the multivariate model. Birth sex and race were no longer significantly 
associated with colonoscopy screening.  Age over 65 (OR=2.46, 96% CI=1.87, 3.26) and having 
insurance (OR=1.67, 95% CI=1.17, 2.39) and being uninsured (OR=0.66, 95% CI=0.50, 0.87) remained 
significant associations with screening. Transgender identity again had the strongest association with 
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Table 8. Demographics and colon cancer screening (colonoscopy) among transgender 
patients and respondents of the New York City Community Health Survey 2011 ≥age 50 
(n=4800): bivariate and multivariate logistic regression models 
 
 Bivariate Multivariate 
Variable OR (95% CI) p-value OR (95% CI) p-value 
Age     
50-64 1.00 <.001 
 
1.00 <.001 
65+ 1.98 (1.73, 2.26) 2.46 (1.87, 3.26) 
Birth sex      
Male 1.00 .035 1.00 .502 
Female 1.15 (1.01, 1.31) 0.93 (0.77, 1.14) 
Gender identity     
Cisgender 1.00 <.001 1.00 <.001 
Transgender 0.1 (.07, 0.14) 0.16 (0.11, 0.23) 
Race/ethnicity     
White (non-Hispanic) 1.00 .020 1.00  
People of color 0.86 (0.75, 0.98)  0.86 (0.71, 1.05) .128 
Employment     
Employed 1.00  1.00 .003 
Unemployed 0.43 (0.34, .54) <.001 0.66 (0.50, 0.87) 
Education   -  
No high school diploma 1.00  -  
High school diploma 1.15 (0.96, 1.37) .123 -  
Insurance     
Uninsured 1.00  1.00 .005 
Insured 2.1 (1.60, 2.74) <.001 1.67 (1.17, 2.39) 
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Current smoking rates were significantly higher among transgender individuals (27.6% vs. 
13.5%, p<.001), Table 8. Birth sex female (OR=0.74, 95% CI=0.66, 0.83) and having a high school 
diploma (OR=0.67, 95% CI=0.58, 0.79) were also associated with lower odds of smoking. Increased odds 
of smoking were associated with being unemployed (OR=2.17, 95% CI= 1.86, 2.53), being non-white 
((OR=1.29, 95% CI 1.15, 1.41) and transgender status (OR=2.45, 95% CI=2.15, 2.79). Insurance status 
was not associated with being a current smoker, p=.634. Age, birth sex, gender identity, employment and 
education were entered to the multivariate analysis. Race and birth sex were no longer associated with 
being a current smoker. Older age and having a high school diploma were associated with decreased odds 
of being a current smoker. Being unemployed (OR=1.62, 95% CI=1.38, 1.97) and transgender status 
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Table 9. Demographics and cigarette smoking among transgender patients and 
respondents of the New York City Community Health Survey 2011 (n=9449): bivariate and 
multivariate logistic regression models 
 
 Bivariate Multivariate 
Variable OR (95% CI) p-value OR (95% CI) p-value 
Age     
18-24 1.00  1.00  
24-29 1.15 (0.87, 1.52) .316 1.06 (.77, 1.47) .712 
30-44 1.13 (0.89, 1.42) .321 1.13 (0.86, 1.48) .391 
45-64 1.01 (0.80, 1.26) .953 1.14 (0.86, 1.50) .370 
65+ 0.39 (0.30, 0.51) <.001 0.47 (0.30, 0.74) .001 
Birth sex      
Male 1.00 <.001 1.00 .305 
Female 0.74 (0.66, 0.83) 0.93 (0.80, 1.07) 
Gender identity     
Cisgender 1.00 <.001 1.00 <.001 
Transgender 2.45 (2.15, 2.79) 1.92 (1.61, 2.28) 
Race/ethnicity     
White (non-Hispanic) 1.00 <.001 1.00 .765 
People of color 1.29 (1.15, 1.41) 1.02 (0.88, 1.19) 
Employment     
Employed 1.00 <.001 1.00 <.001 
Unemployed 2.17 (1.86, 2.53) 1.62 (1.38, 1.97) 
Education     
No high school diploma 1.00 <.001 1.00 <.001 
High school diploma 0.67 (0.58, 0.79) 0.52 (0.42, 0.65) 
Insurance     
Uninsured 1.00 .634 -  
Insured 0.95 (0.77, 1.18) - 
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2.3 Discussion 
Demographics and Healthcare Utilization 
This study demonstrated the diversity of gender identities held by transgender people. There 
were over 50 different terms that people claimed to describe both binary and nonbinary gender 
identities. The current recommended method to identify transgender people has been the two-
step method, publicized by The Williams Institute, which asks both gender identity as well as sex 
assigned at birth.[63] This has been demonstrated to identify a greater number of transgender 
individuals than the one-step question that only asks whether a person is male, female or 
transgender, since there are transgender people who do not identify as trans, and will only check 
the male or female boxes.[64] The two step question has been validated and found to be 
acceptable to both transgender and cisgender people.[65-67] When this study was initiated the 
two-step question at the health center’s registration had not been implemented, resulting in the 
need to use an algorithm consisting of ICD codes, medication history and discordance between 
name and gender as well as chart reviews to identify transgender people. In this analysis we 
discovered that some transgender people will not accurately report their sex assigned at birth; 
there were 44 transgender individuals who chose their affirmed gender rather than sex assigned 
as birth for clinic registration--29 transmasculine (5.13%) and 15 transfeminine individuals 
(1.36%) misreported their birth gender. This raises concerns for their health care since many 
health screenings such as cervical, breast and prostate screening are based on birth sex. In large 
data sets being developed to follow cohorts of transgender people, this should be considered as a 
potential source of misclassification. 
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The very large number of terms used for gender identity can cause some challenges for 
data analysis. Previous papers have reported on the diversity of gender identities.[3, 60] This 
paper has proposed a way to categorize transgender individuals into binary and nonbinary gender 
identities. In this dataset there were few people who identified as nonbinary (<3%) resulting in 
sparse data for analysis, hence the rationale for conducting analyses using umbrella headings of 
transfeminine and transmasculine. Unfortunately, this obscured any health disparities between 
nonbinary and binary identified transgender people which have recently been documented.[68-
70] 
Baseline characteristics 
The transfeminine and transmasculine individuals attending the Center differed in multiple ways. 
Transmasculine people were younger, predominately white, more highly educated, more likely to 
be employed and have stable housing compared with transfeminine individuals. Transgender 
women also had higher rates of current smoking. These findings are consistent with several other 
studies that indicate transgender women experience high levels of felt and enacted stigma often 
resulting in social marginalization, high rates of homelessness, sex work, incarceration, 
depressive symptoms and unhealthy behaviors, such as tobacco use, alcohol, substance use and 
illicit use of silicone[71-75]   
Gender affirming care 
Uptake of gender affirming hormone therapy was high in both groups, with 79% of 
transmasculine and 84% of transfeminine people using hormones. Fewer individuals had 
accessed gender affirming surgeries, possibly because the timing of this chart review preceded 
the overturning of  the longstanding ban on the use of Medicare funds to pay for gender 
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affirming surgeries in 2014 [76] as well as a determination by the Department of Health and 
Human Services in its Final Rule that Section 1557 of the Affordable Care Act addressing sex 
discrimination also included discrimination on the basis of gender identity, stating that “explicit 
categorical exclusions in coverage for all health care services related to gender transition are 
facially discriminatory”.[77, 78] Lastly, New York State Medicaid did not change its exclusion 
on transition related care until 2015.Over half of transfeminine individuals at the time of this 
study had public insurance and therefore would not have been able to easily access surgeries. 
 In this report 26.2% of transfeminine individuals had accessed any gender affirming 
surgery compared to 41.6% of transmasculine individuals. The most common surgery for 
transmasculine people was bilateral mastectomy (39.3%) whereas the most common procedure 
for transfeminine individuals was breast augmentation (15.3%). The first US Transgender 
Discrimination Survey was published in 2011, around the same time as this retrospective chart 
review, and included the experiences of 7500 transgender respondents across the USA. 
Similarly, about 80% of transgender women and 69% of transgender men had accessed hormone 
therapy. Approximately the same number of transgender men had accessed mastectomy (43%), 
but the rates of genital surgeries were much higher in the survey - metoidioplasty 4%and 
phalloplasty 2%. Twenty one percent  of transgender women had undergone breast augmentation 
and 23% vaginoplasty, both higher than reported in this study.[39] This difference in surgery 
rates between The US Transgender Discrimination Survey and patients at the Center is 
possibility due to lower unemployment rates observed among study participants (14% vs. 40%) 
and therefore greater ability to pay for these surgeries out-of-pocket.  
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Colonoscopy rates 
The 2016 US Preventive Services Task Force recommendation on screening for colorectal cancer 
states that screening for colorectal cancer should occur in adults aged 50 to 75 years.[79] There 
are different methods used for screening including colonoscopy, flexible sigmoidoscopy and 
stool based tests such as the fecal occult blood test and the fecal immunochemical test.[80] 
Colorectal cancer screening rates are increasing nationally and are currently over 60% for 
eligible adults 50 years and older.[81] The results from this survey, however, showed extremely 
low utilization of colonoscopy of <25%. Even after adjusting for age, race, education, birth sex, 
employment and insurance, transgender status remained strongly associated with failure to 
undergo screening. Transgender people frequently face stigma and discrimination in healthcare 
settings that may deter them from seeking preventive health care or delaying necessary 
healthcare services.[39, 82] including low rates of cervical pap tests in transgender men.[83] 
Only one other study has examined colonoscopy rates in this population using data from the 
Behavioral Risk Factor Surveillance System Surveys 2014-2016. In that investigation higher 
rates of colorectal cancer screening were seen among transgender men and lower lifetime rates of 
endoscopy (colonoscopy and sigmoidoscopy) for gender nonbinary people. Although there was a 
trend to lower endoscopy rates among transgender women, this was not significant.in the 
multivariable analysis.  
Smoking Rates 
In this study current tobacco use was approximately 25% among transmasculine and 29% among 
transfeminine people. Several studies have demonstrated elevated tobacco use among 
transgender people from 30-83%[74, 75] and a recent national study demonstrated high previous 
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30 day use of tobacco products among transgender people 40% vs 25% among cisgender people, 
as well as a higher smoking prevalence among transmasculine compared with transfeminine 
individuals, which differed from what was found in this report.[76] The analysis with the NYC 
CHS confirmed that an excess of current smoking exists in transgender populations, even after 
adjusting for age, race, birth sex, employment and education, which are all factors known to be 
associated with tobacco prevalence. 
Limitations 
The main limitation for this study is that the transgender patients were from a single clinic in 
New York City and therefore may not be representative of transgender patients across the US. 
Clinic procedures may have been associated with the low colorectal screening rates, e.g., if 
providers did not offer screening. Additionally, data within the medical records, especially those 
that rely on self-report (e.g., cigarette smoking) may be inaccurate. Patients may have under-
reported their smoking behavior thereby introducing bias, known as social desirability bias. The 
result of this bias however would have been attenuation of the odds associated with smoking. 
Other inaccuracies may be due to medical providers not entering information about risk such as 
cigarette smoking in the medical record, however this also would have attenuated the odds.  
The data used in this analysis came from a chart review conducted over 9 years ago and it 
is possible that trends in health care uptake may have changed due to greater accessibility of 
insurance and health settings willing to provider gender affirming care. The study is still relevant 
however due to the fact that there have been few studies published during this time examining 
rates of colorectal cancer screening and few that have investigated other primary care outcomes. 
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Although attempts were made to adjust for potential confounders, it is possible that 
residual confounding or unknown confounders existed. Finally, the use of the NYC CHS data set 
for comparison assumed that a very low proportion of the respondents in the survey were 
transgender. Based on current estimates, about 0.4 to 0.6% of the population is transgender. This 
equates to 31-47 transgender people who may have been misclassified as cisgender in the data 
analysis and would have been unlikely to change the results. 
2.4 Conclusion 
This study has described the baseline characteristics of transgender people engaged in medical 
care, including the utilization of gender affirming care, uptake of preventive services 
(colonoscopy) and prevalence of cigarette smoking. Identification of transgender people within 
datasets is challenging but needs to be prioritized in order to better identify potential health care 
disparities. For example, this study revealed extremely high rates of cigarette smoking, double 
that of other New Yorkers. In addition, the uptake of colonoscopy for colorectal cancer screening 
was about one third of the rate expected.  
This paper provides an algorithm for identifying transgender people in large data sets in 
situations where the 2-step method has not been implemented. It also offers a caution that 
misclassification of birth sex may occur, an issue not previously reported, that can result in 
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Chapter 3: Health Outcomes of Transgender Women who have 
Undergone Vaginoplasty Surgery: A Scoping Review 
 
3.1 Background 
Transgender individuals (i.e., those whose gender identities differ from the sex which they were 
assigned at birth [6]) are estimated to account for 0.39% of the United States adult population or 
approximately 1 million people. [1] Further estimates place the number of transgender adults at 
25 million worldwide.[58] Some transgender individuals experience gender dysphoria, or 
distress related to the incongruence between their gender identity and their sex assigned at 
birth[84] and may seek out hormonal or surgical interventions in addition to social or legal 
changes, e.g., changing their name and/or gender marker.[6] Hormones and surgeries help to 
align a transgender individual’s physical appearance with their affirmed gender identity. 
Surgeries undertaken by transmasculine individuals (those assigned female at birth) include chest 
reconstruction (usually bilateral mastectomy) and genital surgeries, including metoidioplasty, 
phalloplasty, scrotoplasty, hysterectomy, oophorectomy and vaginectomy.[6, 85] Surgeries 
undertaken by transfeminine individuals (those assigned male at birth) include breast 
augmentation, facial contouring, chondrolaryngoplasty (reduction of the “Adam’s apple”), and 
genital surgeries, including orchiectomy, penectomy and vaginoplasty (creation of a vagina).[6, 
85] The first vaginoplasty surgeries involved removal of the genitals (penectomy and 
orchiectomy) followed by a second stage procedure to create the vagina using split skin grafts 
(SS).[86] This technique using skin was based on surgeries done on cisgender (i.e., not 
transgender) women with congenital absence of the vagina and was first described in the 1890s 
by Robert Abbe.[87] Modern day vaginoplasty procedures in transgender women generally fall 
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into 2 types, penile inversion (PI) that uses penile and sometimes scrotal skin, and intestinal or 
colo-vaginoplasty (CO) that uses bowel for the neovaginal lining.[85, 86, 88, 89]  
A large national survey (2015 US Trans Survey) of approximately 28,000 transgender 
and gender non-binary participants indicated that although only 5% of transgender men had 
undergone phalloplasty or metoidioplasty, 44% planned to have it one day. Among transgender 
women participants, 12% had undergone vaginoplasty or labiaplasty, however 54% reported that 
they wanted it some-day.[60]  
For many years, access to these gender-affirming interventions, especially surgeries, were 
limited. This was predominantly due to insurance companies excluding coverage, calling such 
interventions “cosmetic” or “experimental” or denying payment on the basis of pre-existing 
conditions.[90] In the 2015 US Trans Survey,  25% of individuals had been denied insurance 
coverage for hormones and 55% for surgical interventions within the previous year,[60] but the 
US landscape for insurance coverage of transgender-related care is starting to change. In 2014 
the longstanding ban on the use of Medicare funds to pay for gender affirming surgeries was 
lifted.[76] Subsequently, the Department of Health and Human Services (HHS) in its Final Rule 
determined that Section 1557 of the Affordable Care Act addressing sex discrimination also 
included discrimination on the basis of gender identity, stating that “explicit categorical 
exclusions in coverage for all health care services related to gender transition are facially 
discriminatory”.[77] Changes in the private sector have also occurred with an increasing number 
of employers beginning to include insurance coverage for gender-affirming care as a benefit 
within commercial plans.[78]  
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Evaluation of insurance claims data has verified a year-by-year increase in the number of 
people accessing gender-affirming surgeries.[91] A study examining 37,827 hospital inpatient 
visits from people having an ICD code of gender identity disorder (GID) or transsexualism 
demonstrated that 3,586 (approximately 10%) involved gender-affirming genital surgery. Of all 
gender affirming surgeries conducted in the time periods 2000-2005 and 2006-2011 the 
proportion of genital surgeries increased from 72% to 83.9%, (P = .003).[92] 
The increase in the number of transgender individuals undergoing gender affirming 
surgeries has important consequences for primary care providers in the US. Several surveys have 
indicated that curricula in nursing, medicine and dental schools do not include adequate content 
in transgender health care[93-96] and that clinicians are not sufficiently prepared to provide 
culturally competent trans-affirming care. [97-100] A survey of 178 medical schools on lesbian, 
gay, bisexual and transgender related curricula revealed that content related to sex reassignment 
surgery was one of the least likely to be included.[94]  
The current guidelines usually followed by healthcare providers who care for transgender 
patients include The World Professional Association for Transgender Health’s Standards of Care 
(SOC) for the Health of Transsexual, Transgender, and Gender Nonconforming People[6] and 
the Endocrine Society’s Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent 
Persons: An Endocrine Society Clinical Practice Guideline [41] neither of which provides 
comprehensive information about immediate or long term postoperative care issues. Aggregating 
existing research and identifying gaps in knowledge will be useful for clinicians providing 
primary care and surgeons, inform future research, as well as assist policy makers seeking to 
create quality measures for care of transgender people. 
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Several narrative and systematic reviews [47, 48, 50-53] have examined long-term health 
outcomes related to cross-sex hormone therapy; however, to our knowledge, although there have 
been systematic reviews of surgical techniques, short term health outcomes and a recent review 
of outcome measures,[54-57] there have been no comprehensive reviews investigating short and 
long-term health outcomes related to these surgeries for transgender women who have undergone 
genital surgery.  
This paper will focus on health outcomes after gender affirming genital surgery in 
transgender women rather than both transgender women and men because there is more 
standardization of feminizing surgeries, allowing for better comparison of outcomes over time 
and across countries. With masculinizing surgeries there is considerable variation in the 
procedures performed, e.g., metoidioplasty with or without urethral lengthening, phalloplasty 
using different graft donor sites, optional procedures such as testicular implants, penile 
protheses, hysterectomy and vaginectomy, making such comparisons difficult.  
Hence, the aim of this review was to summarize the peer reviewed literature regarding 
genital surgery (vaginoplasty) in transgender women, including a description of different surgical 
techniques, quality measures, postoperative complications and long-term health outcomes. As a 
literature review of the topic has not previously been conducted, a scoping review was 
undertaken since  that is a preferred method to undertake for formative research in an area that 
has not been reviewed comprehensively.[101]  
      
 
47 
   
 
3.2 Methods 
We followed the 5-step framework for a scoping review outlined by Arksey and O’Malley[102, 
103] including (1) identifying the research question, (2) identifying relevant studies, (3) study 
selection, (4) charting the data and (5) collating, summarizing and reporting the results[101] 
Stage 1: Identifying the research question  
What is the scope of the literature related to vaginoplasty surgery health outcomes? What are the 
gaps that can be addressed in future research? 
Stage 2: Identifying relevant studies 
The first vaginoplasty surgeries in transgender women were reported as early as the 1920’s,[86] 
however the modern technique of penile-inversion vaginoplasty was developed in the mid 1950’s 
by Dr Georges Burou.[104] We decided therefore to conduct a search of relevant studies 
published between 1956 and 2017. 
The initial search strategy used a combination of key words and relevant medical subject 
headings (MeSH), and included the following databases: PubMed, EMBASE and Cumulative 
Index to Nursing and Allied Health Literature and Web of Science. We also hand searched issues 
of the International Journal of Transgenderism (IJT), the first peer-reviewed academic journal 
covering research on gender dysphoria from the first volume July - September 1997 through 
December 2018. The terminology related to transgender persons has changed over the time 
frame included in the search, for example transgender women today would have been referred to 
as transsexual men or transvestites in the early studies, requiring the use of multiple search terms 
(Table 1). 
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Table 1. Search terms used for the database search 












“Sex Reassignment”[Mesh]  
Sex reassignment*[tiab]  
Sex change*[tiab] 
Gender reassignment*[tiab]  
Gender change*[tiab]  
Sex reassignment*[ot]  
sex change*[ot]  
 
Stage 3: Study Selection 
All study designs were included if they addressed the research question: What is the scope of the 
published research(?) related to vaginoplasty surgery health outcomes?  Due to the relative 
paucity of literature in this field we did not reject studies based on sample size and also included 
case reports that addressed complications.  
Specific inclusion criteria were: 
1. Study design: Case reports, case series, retrospective and prospective studies 
2. Year: Published between 1/1/1956 and 12/31/2018 
3. Outcomes: Study included information on complications or outcomes after vaginoplasty 
or included at least 1 quality measure 
4. Surgery: Primary vaginoplasty surgery 
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5. Gender: Transgender or nonbinary identity assigned male at birth 
6. Age: Adult (16+) 
7. Full article available in English 
Specific exclusion criteria included published reviews of surgical techniques without outcomes 
data, opinion pieces, revisions or secondary surgeries, surgery conducted on children or intersex 
individuals, and vaginoplasty surgery on cis-gender women (i.e., non-transgender women) for 
congenital vaginal atresia or other disorders of sex development and studies that included 
vaginoplasty surgeries in both transgender women and cis-gender women but that did not 
disaggregate outcomes for these 2 groups. English language abstracts were reviewed to 
determine the breadth of worldwide literature, although articles not available in English were 
excluded from the final mapping. 
Study titles and abstracts were exported to Covidence (https://www.covidence.org/home), 
an online systematic review citation software that allows 2 or more people to independently 
conduct screening of abstracts, full-text review and study selection. Two reviewers (AR and PC) 
identified studies through review of study titles and abstracts to identify articles appropriate for 
full text review. Available options in Covidence were Yes, No and Maybe. Discordant answers 
resulted in a full review of the article. A third reviewer (AH) was available for consultation if 
consensus could not be reached. The data were extracted and entered into an Excel data base that 
included the following parameters: Publication year, Country, Study design, Sample size, Patient 
demographics (age), Type of surgery (penile inversion “PI”, colo-vaginoplasty “CO” or split skin 
graft “SS”), Duration of follow up, Surgical outcomes, Complications, Quality measures, Key 
findings. Articles that included more than one study design, e.g., an article that included a 
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retrospective chart review of all surgical cases as well as prospective follow-up of a subset of 
patients contributed data to two different study designs. 
3.3 Results 
Using these database search strategies, 3,102 citations were identified, of which 605 were 
duplicates. The hand search of the International Journal of Transgenderism yielded 2 additional 
articles that met initial screening criteria. Screening of the remaining 2499 papers (review of 
titles and abstracts) determined that 2,131 were irrelevant or did not meet the inclusion criteria. 
Full text review was completed for 368 papers, after which 265 were eliminated: 80 were 
published conference abstracts, 60 did not provide post-vaginoplasty outcomes, 40 did not have 
full text available in English, 19 included ineligible surgeries (e.g., secondary procedures and 
revisions), 18 were review articles, 12 were letters to the editor or commentaries, 17 did not 
provide data on transgender women (vaginoplasty surgeries in cisgender women or intersex 
people with vaginal agenesis or data were not disaggregated between cis-gender and transgender 
women), 10 were studies that had been previously published in another journal and data were 
already included, 4 had no full text available, 4 were videos only and 1 was excluded as it 
focused on pediatric populations. The final sample comprised 103 studies for inclusion in this 
scoping review. (Figure 1) 
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International Journal of Transgenderism 
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Records after duplicates removed 
(n = 2499) 
Records screened 
(n = 2499) 
Records excluded 
(n =2131) 
Full-text articles assessed for 
eligibility 
(n = 368) 
Full-text articles excluded, 
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(n = 265) 
80 Conference abstracts 
60 No postsurgical 
outcomes 
40 Full text not in English 
19 Not eligible surgery 
18 Review articles 
17 Not transgender women 
12 Commentary/Letter to 
Editor 
10 Duplicate publication 
4 No Full text available 
4 Video links 
1 Pediatric population 
Studies included in 
qualitative synthesis 
(n = 103) 
Duplicates removed 
(n =605) 
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Timeline 
There has been a steady increase in the number of published articles on vaginoplasty surgery that 
met the eligibility criteria. In the years 1970-1979 6 articles were published compared to 47 in 
the years 2010 to 2018 (Figure 2). 
Figure 2: Publications by Year 1970-2018 
 
Geographical Representation 
The majority of articles were published in the United States and Europe. European gender 
centers published the majority of articles (62%) followed by United States and Canada (17%) 
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Figure 3: Publications by Country 
 
Study Designs 
The majority of publications (53) were retrospective chart reviews that originated from both high 
and low volume surgical centers worldwide reporting on predominately short-term perioperative 
outcomes for penile inversion and intestinal (colon) vaginoplasty surgery for 3,853 women. The 
number of surgical cases included in each article ranged from 2 to 500. Postoperative 
complications from these retrospective reviews are listed in Table 2. Twenty of these studies 
used mixed methods and, in addition to chart reviews to assess perioperative complications, also 
included a prospective component (e.g., using surveys or in person interviews) to assess health 
outcomes at a later date. [105-124]  Thirty-six publications were case reports or case series 
predominately describing uncommon surgical complications and long-term outcomes. Thirty-
four publications included prospective data and compared pre- and post-operative outcomes or 
compared outcomes between transgender women and cisgender women, transgender men or 
normative population data.  
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Outcome Measures for Vaginoplasty 
Over the years there have been multiple outcomes investigated as measures of successful 
surgery. These have included vaginal depth and width, aesthetics, sensation, ability to have 
sexual intercourse (function), ability to orgasm, romantic/sexual partnerships, arrests/criminality, 
feeling more “feminine,” and quality of life (Table 2).  
Table 2: Vaginoplasty Outcome Measures  
Outcome Measures Studies 
Sexual adjustment: Sexual intercourse 
frequency, pleasure, sensation, sexual 
partners, ability to orgasm 
[89, 105, 106, 108, 111-113, 116, 117, 119, 120, 
122, 124-135]  
Aesthetics: patient and/or surgeon graded [107, 108, 111-113, 117, 120, 122, 124, 126, 128, 
129, 133-140] 
Satisfied with surgery [89, 108, 110, 116, 117, 120, 122, 124-127, 129, 
134, 137, 141-145] 
Interpersonal relationships/family/friends [71, 105, 109, 111, 112, 116, 125-127, 129, 133, 
134, 138-140, 143, 146-148] 
Quality of life measures [71, 105, 109, 116, 119, 127, 129, 131, 134, 135, 
143-147] 
Vaginal depth/width [89, 106, 111, 113, 117, 120, 125, 129, 147] 
Subjective well being [119, 132, 135, 144, 146, 149] 
Married/relationship yes/no [71, 130, 146, 150] 
Social adjustment [13, 105, 132, 138, 147] 
Economic adjustment/Employment [134, 143, 146, 147] 
Feels more feminine after surgery [127, 140, 150] 
Education level [127, 140, 147, 150] 
Criminality/arrests [147, 151] 
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Perioperative Complications 
Perioperative complications were mostly documented by retrospective reviews of surgeries 
performed at high volume gender clinics. We found no published articles that discussed the 
expected timeline for complications experienced by transgender women having gender affirming 
surgery. The majority of the studies included in this paper provided information beyond 
hospitalization and immediate perioperative complications, providing a range of 6 months to 13 
years follow up after surgery. The most frequently reported postoperative complications were 
vaginal stenosis, urethral strictures, rectovaginal fistula, bleeding, and infection. Two studies 
provided additional details regarding timing of the complications, e.g., whether perioperative, at 
the first follow-up appointment or later [115] or ≤1 year vs. > 1 year.[122] 
Table 3 provides the full list of vaginoplasty complications reported and number of studies in 
which these were mentioned. 
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30 [106-112, 115, 117, 120, 122, 128, 133, 137, 139, 
150, 152-161] 
Vaginal stenosis 30 [89, 106, 108, 110, 111, 115, 117-120, 122, 124, 125, 
128, 130, 136, 137, 139, 150, 152-162] 
Rectovaginal fistula 21 [105, 108, 111, 117, 122, 124, 128, 130, 137-139, 
146, 150, 152, 155, 157-159, 162, 163] 
Bleeding 17 [108, 115-118, 124, 128, 148, 152, 158-165] 
Infection 15 [89, 105, 112, 115, 118, 122, 124, 128, 139, 146, 150, 
152, 158, 161, 165] 
Rectal lesion/injury 11 [112, 115, 117, 118, 128, 139, 146, 159-161, 163] 
Short vagina/shrinkage 10 [105, 108, 111, 118, 128, 138, 139, 146, 162, 166] 
Urination problems 10 [105, 107, 115, 118, 124, 128, 133, 160-162] 
Pain 9 [105, 108, 118, 120, 124, 128, 156, 157, 162] 
Vaginal prolapse 8 [112, 115, 122, 124, 128, 150, 154, 158] 
Full/partial flap failure 7 [106, 109, 115, 117, 128, 156, 161] 
Urethral/Vesicovaginal 
fistula 
7 [112, 122, 128, 139, 150, 158, 162] 
Retention of bulbous 
spongiosum 
6 [106, 109, 110, 115, 122, 155] 
Hematoma 5 [106, 124, 128, 139, 158, 166] 
Wound dehiscence 4 [128, 159, 162, 164] 
Delayed healing 4 [118, 148, 151, 160] 
Clitoris too large 3 [109, 118, 148] 
Necrosis glans penis 3 [109, 112, 139] 
Excessive vaginal secretion 2 [124, 157, 167] 
Venous thromboembolism 3 [89, 115, 150] 
Excess labial tissue 2 [128, 148] 
Hair in vagina 2 [108, 115] 
Vaginal skin defect 2 [111, 158] 
Miscellaneous vaginal 
complaint 
2 [106, 162] 
Compartment syndrome 2 [128, 146] 
Dilation problems 2 [105, 162] 
Granulation tissue, Phantom 
penis, Pneumothorax, 
Colitis, Stroke, Bowel 
obstruction, Diarrhea, 
Bladder tear, Torn 
gastrocnemius muscle 
1 [89, 105, 117, 120, 122, 124, 146, 165] 
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Vaginoplasty Outcomes from Case Reports 
Many of the publications (n=36) were case reports or case series reporting unusual or novel 
occurrences. These case reports/case series included outcomes on 51 women, 24 of whom had 
penile-inversion and 18 who had colo-vaginoplasty surgery and 1 split skin graft. For 9 women 
the type of tissue used for the surgery was not provided. Age at presentation (where provided) 
ranged from 19 to 57 (average age 38 years). The time between surgery and the complication or 
unusual occurrences ranged from 1 day to 45 years, average 8.4 years. Case reports (Table 4) 
included neovaginal infections such as Neisseria gonorrheae, condyloma acuminata, Herpes 
simplex and bacterial vaginosis. These infections would fall under the category of “unusual or 
novel occurrences” since there are few data on neovaginal infections. Medical complications in 
women who had neovaginas constructed from bowel tissue included diverticulitis, diverticulosis, 
diverticular phlegmon, ulcerative colitis and diversion colitis. Other complications reported in 
the case reports included vaginal dysplasia and cancer. 






Table 4: Summary of Case Reports 
Author/Year Sample 
size 







Hennigan 1992[168] 1 42 16 years CO Ulcerative colitis 
Freundt 1994[169] 1 41 3 years CO Vaginal prolapse 
Bodsworth 1994 [170] 1 37 14 years PI Neisseria gonorrheae 
Hage 1995 [157] 1 42 6 years CO Diversion colitis 
Hage 1996 [171] 7 NR 19 years NR Labial mass from retained epididymis 
NR 9 years NR Dyspareunia caused by cavernous tissue 
remnant  
NR 10 years NR Chronic labial swelling due to fistula 
NR 12 years NR Chronic labial swelling due to fistula 
NR 1 year NR Prostatic fistula 
NR 12 year SS Labial abscess 
NR NR CO Labial abscess 
Van Engeland 2000[172] 3 37 7 years PI Condyloma acuminata 
36 NR CO Diversion colitis 
45 10 years CO Diversion colitis 
Lawrence 2001[173] 1 36 5 years PI Vaginal intraepithelial neoplasia 
Liguori 2001[174] 1 39 4 months CO Perforation of neovagina/peritonitis 
Harder 2002[175] 1 42 18 years PI Squamous cell carcinoma 






Abraham 2004 [176] 1 57 25 years CO Acute diverticular phlegmon 
Liguori 2004 [177] 1 27 6 months PI Condyloma acuminata 
Condous 2006 [178] 1 40 16 years PI Vaginal prolapse 
Jain 2007 [179] 1 26 2 years PI Bacterial vaginosis 
Namba 2008 [180] 1 52 6 months PI Phantom erectile penis 
Sukumaran 2009 [181] 1 48 18 years CO Neovaginal calculi 
Yang 2009 [182] 1 23 20 months CO Condyloma gigantea 
Lin 2010 [183] 2 32 10 years PI Urethral stricture 
46 27 years PI Urethral stricture 
Amirian 2011 [184] 1 52 34 years CO Neovaginal perforation 
Aminsharifi 2012 [185] 1 24 8 months CO Entrapment of metallic dilator  
Altomare 2013[186] 1 31 2 weeks PI Recto-neovaginal fistula 
Deliktas 2018 [187] 1 33 7 years PI Neovaginal perforation 
Rezwan 2014 [188] 1 54 13 months NR Bilateral ureteric obstruction  
Fernandes 2014 [189] 1 53 21 years PI Squamous cell carcinoma 
vanderSluis 2015 [190] 1 33 3 years CO Neisseria gonorrheae 
Shimamura 2015[191] 1 33 4 years CO Perforation of neovagina/peritonitis 
Aghayev 2015 [192] 1 39 8 years CO Neovaginal variceal bleeding 
Bakker 2015 [193] 1 56 31 years CO Diverticulosis 
Matsuki 2015 [194] 1 23 2 years PI Condymoma acuminatum 






Hyun Jong Kim 2015 [195] 1 29 6 years PI Pelvic inflammatory disease 
Suchak 2015 [196] 4 NR 6 months  PI Vaginal hair and odor 
NR 5 years NR Vaginal atresia 
NR 2 years  NR Corpus spongiosum with irregular urination 
NR 9 months  NR Granulation tissue 
Negenborn 2017 [197] 1 18 24 hours CO Necrotizing fasciitis/death 
Elfering 2017 [198] 1 24 18 months PI Herpes simplex 
Labanca 2017 [199] 1 19 1 year PI Vulvar condyloma 
Thewjitcharoen 2018 [200] 1 28 18 months CO Bowel obstruction and hemorrhagic 
necrosis 
DeHaseth 2018 [201] 5 30 12 months PI Neovaginal candidiasis 
47 20 months PI Neovaginal candidiasis 
30 14 months PI Neovaginal candidiasis 
61 1 month PI Neovaginal candidiasis 
25 3 months PI Neovaginal candidiasis 
Bollo 2018 [202] 1 78 45 years PI Squamous cell carcinoma  
 
†Vaginoplasty type: PI= penile-inversion, CO=colo/intestinal, SS= split skin graft 
 *NR=not reported  
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Prospective Studies  
Thirty-four studies included a prospective design to investigate longer term vaginoplasty 
outcomes; these used various methods to investigate the impact of surgery on medical and 
psychosocial outcomes, including pre-post measures of change, the use of concurrent and 
historical comparison groups as well as comparisons to normative population data. One study 
compared outcomes among individuals offered early or delayed surgery and found significant 
improvements in social and work activity among the group that had undergone early surgery[13] 
Three studies compared outcomes in transgender people postoperatively to cisgender people or 
community level data [203-205] while others compared pre- and post-surgical measures without 
an external comparison group. Women were evaluated between 0.5 and 23 years after 
undergoing surgery. The studies and outcome measures are summarized in Table 5. 
Early studies focused on the impact of surgery on psychosocial functioning. Measures of 
success were demonstrated by the woman maintaining or improving employment prospects, 
being in a relationship and preferably married to a cisgender man, blending into society, not 
socializing with transgender people and avoiding criminal activities. Hunt 1979[147] and 
Ross[107] both used the Minnesota scale that assessed postoperative women in 5 domains: 
Economic adjustment, interpersonal relationships, psychopathology, sexual adjustment and 
family reactions. Although modest improvements were seen in most domains, the surgery did not 
positively impact on employment or psychopathology, which included subcategories of mental 
status, drug use and legal problems such as criminal activities.  
Many of the studies investigated the aesthetics of the genitals after surgery. Aesthetics 
were measured in different ways, including asking women about overall satisfaction  [105, 107, 
108, 111-113, 117, 120, 122, 124, 126, 128, 129, 133-140] and more specifically about 
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satisfaction with the appearance of the new genitals.[107, 108, 110, 112, 113, 115, 117, 120, 121, 
132, 133, 143, 206] In all of the studies the vast majority of women were highly satisfied with 
the aesthetics of their surgery by whatever standard was used. 
Some studies attempted to use a more objective measure by having the surgeons or other 
professionals rate the appearance of the neovagina and external genitals, either by rating photos 
or doing a pelvic exam.[108, 111, 113, 120, 123, 133]. In one study lay people as well as 
professionals rated the photos, with cisgender women giving the lowest scores of all raters.[123]  
In recent years several studies have used scales validated in cis-women such as the Female 
Genital Self-Imaging Scale (FGSIS).[207] These have shown high scores when applied to 
postoperative transgender women and similar to normative data in cisgender women.[123, 167, 
204, 208]  
Another documented measure of successful surgery included having adequate vaginal 
dimensions (width and length). Several studies accomplished this by asking women if they were 
satisfied with the length/size of the vagina. In all studies women were highly satisfied.[107, 112, 
115, 117, 122, 124, 133, 143, 206] In other studies the surgeons measured the vagina using 
vaginal stents or dilators.[108, 113, 117, 133, 208] At times this did not correlate with the 
patients’ viewpoint. In general women were usually satisfied, even if the surgeon documented a 
“short” vagina.[133] 
Sexual function and orgasm were studied by most of the investigators. The rates of 
orgasm ranged from to 50-96%.[110-112, 115, 117, 120, 130, 134, 140, 142, 209-211] 
Quality of life (QOL) was measured using different scales, including the Short Form 36 
(SF-36) Health Survey),[212]  the World Health Organization Quality of Life (WHOQOL-
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100),[213]  the QOL Fragen zur Lebenszufriedenheit Module [FLZM][214] and The King’s 
Health Questionnaire.[215] QOL appeared to improve after surgery, [131, 141, 144, 203-205, 
216, 217] although scores were sometimes lower than the general population at baseline.[205, 
217]  
In addition to QOL, several studies have also evaluated happiness and well-being, using 
The Subjective Happiness Scale,[218] Satisfaction With Life Scale and [219] Cantril’s Ladder of 
Life Scale.[220] Happiness scores stayed the same [132] or improved after surgery.[204] One 
study objectively examined anxiety and depression. In this study 20 women who had undergone 
vaginoplasty surgery 2 years prior were compared to 20 who were awaiting their surgery. At 
intake and at standard timepoints the Crown Crisp Experiential Index (CCEI) measured anxiety 
and anxiety and depression. Women who underwent surgery were found to be more active 
socially, in sports, more likely to remain employed. The average CCEI scores improved after 
surgery but declined for those awaiting surgery. [221] A second study, Papadopulos et al. also 
reported a trend to lower depression/anxiety scores postoperatively (p < 0.01).[141] 
The Female Sexual Function Index[222] is a scale validated in cisgender women that 
scores sexual desire, frequency of sexual intercourse, arousal, satisfaction, lubrication, emotional 
closeness and pain. The scores among transgender women who had undergone
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vaginoplasty were usually lower than corresponding normative values in cisgender women [123, 
135, 204, 223] and reached normal values in two studies.[131, 167] 






Table 5: Prospective Studies: Outcome measures 
 
Author/Year Country Sample 
size 
Time since surgery Outcome Measures 
Hunt 
1979[147] 
USA 17 Average 8.2 years Psychosocial scale: economic adjustment, interpersonal 




Denmark 23 Average 6 years 
(1-23) 
Psychosocial scale: employment, marital status, social contacts, 
somatic conditions, psychiatric conditions, sexual life 
Kuiper 
1988[132] 
Netherlands 55 Average 5.5 years 
(1 month-14.8 
years) 
Subjective wellbeing, self-perception, satisfaction with behavior, 
integration of gender role, confidence in gender role, body 
satisfaction, regret, suicidality 
Blanchard 
1987[133] 
Canada 22 Average 4.4 years 
(0.5-11.8 years)   
Aesthetics, vaginal depth and width, sexual function 
Ross 
1989[107] 
Australia 14 Average 3.7 years Aesthetics, vaginal dimensions, psychosocial scale (Hunt and 
Hampson)[224]: economic, interpersonal relations, 
psychopathology, sexual adjustment 
Stein 
1990[120] 
USA 10 5-48 months Aesthetics, functional outcome, dilator use, psychosocial scale: 
economic, social, sexual 
Mate-Kole 
1990[221] 
UK 20  Crown Crisp Experiential Index[225], Bern Sex Role 
Inventory[226], psychosocial scale: social, economic, sexual 
Van Noort 
1993[108] 
Netherlands 27 1-103 months Aesthetics, function, vaginal dimensions, sexual life 
Rakic 
1996[134] 
Serbia 22 ≥ 6 months Psychosocial (Adjustment to Sex Reassignment Surgery 
Questionnaire): attitude to body, relationships, sexual activity, 
occupational functioning 








Sweden 40  Aesthetics, function, psychosocial: sexual identity, family 
relationships, employment, economic situation 
Rehman 
1999[110] 
USA 28 ≥ 3 years Aesthetics, function, sexual life, satisfaction with surgery, quality 
of life, psychosocial: relationships, employment adjustment 
Perovic 
2000[111] 
Serbia 89 Average 4.6 (0.25-
6) years 




Germany 31 ≥ 6 months Aesthetics, function, sexual life 
Kwun Kim 
2003[113] 
South Korea 26 Average 5 years 
(1-10 years) 





≥ 1 year Biographical Questionnaire for Transsexuals and 
Transvestites,[227]  Body Image Scale,[228] satisfaction with 
surgery, sexual life, sexual relationships 
Lobato 
2006[229] 




UK 70 Average 56 (8–
351) days 
Aesthetics, function, sexual life 
Imbimbo 
2009[143] 
Italy 139 12-18 months Aesthetics, function, sexual life, satisfaction with surgery, 




Belgium 70 ≥ 6 months Physical and mental health (SF-36 Short Form 36 Health 
Survey),[212] body image, Female Sexual Function Index, sexual 
life,[222] sexual relationships 
Kuhn 
2009[203] 
Switzerland 52 Average 15 years 
(8-23) 
King’s Health Questionnaire,[215] quality of life, health and 
satisfaction 








France 15 ≥ 2 years Physical and mental health (SF-36 Short Form 36 Health 
Survey),[212], Eysenck Personality Inventory[230] 
Amend 
2013[117] 
Germany 24 Average 39.7 
months (16-69 
Aesthetics, function, vaginal dimensions, sexual life 
Tavakkoli 
2014[121] 
Iran 112 13.3±6.7 months Aesthetics, function, satisfaction, sexual life 
Morrison 
2015[122] 
USA 83 Average 2.2 years Aesthetics, function, satisfaction, sexual life 
Buncamper 
2015 
Netherlands 49 4.1 ± 1.0 years Aesthetics, Female Sexual Function Index (FSFI),[222] the 
Amsterdam Hyperactive Pelvic Floor Scale—Women (AHPFS-
W), the Female Genital Self-Imaging Scale (FGSIS),[207] and 
short questionnaire for self-evaluation of vaginoplasty 
Castellano 
2015[131] 




Netherlands 31 Average 2.2 years Subjective Happiness Scale,[218] Cantril’s Ladder of Life 
Scale,[220] Satisfaction With Life Scale,[219] the Female Genital 
Self-Imaging Scale,[207] the Female Sexual Function 
Index,[222] the Amsterdam Hyperactive Pelvic Floor Scale—
Women, postoperative satisfaction survey. 
Cardoso 
2016[216] 




Sweden 190 1, 3, and 5 years≥ Short Form-36 Health Survey (SF36)[212] 
Papadopulo
s 2017[205] 
Germany 47 average 19 months Quality of Life - QOL Fragen zur LebenszufriedenheitModule 
[FLZM][214]; Self-developed questionnaire: aesthetics, function, 
socioeconomic issues and postoperative satisfaction 








Netherlands 100 Average 1.8 years 
(range, 1.0 to 3.7 
years 
Aesthetics, function, satisfaction, vaginal dimensions, sexual life, 
the Female Sexual Function Index,[222] the Female Genital Self-




Thailand 15 ≥ 1 year The Female Sexual Function Index[222], The Female Genital 
Self-Image Scale. [207] 
Zavlin 
2018[206] 
Germany 40 6 months Self-developed scale: Esthetics, function, satisfaction, sexual life 
Massie 
2018[124] 
Netherlands 117 21 months (13-24) Aesthetics, function, satisfaction, sexual life 
 
  




Overview of Included Studies 
The goal of a scoping review is to map the existing published literature, summarize research 
findings and identify gaps and opportunities for future research. One of the strengths of this 
review was inclusion of a wide range of study designs, including case reports/case series, 
retrospective and prospective studies, that could provide comprehensive health outcomes data at 
different timepoints for transgender women who had undergone vaginoplasty surgery. The 
number of publications describing clinical outcomes increased five-fold from the 1970s to 2000s, 
possibly reflecting improved insurance coverage, greater access to trained surgeons as well as 
greater visibility and acceptance of transgender people. This is consistent with studies showing a 
greater number of gender-affirming genital surgeries over the last 5 years.[91, 92] Most of the 
studies were undertaken in Europe and North America. Many of the papers were published in 
English, therefore the majority of papers on this subject were included. The paucity of published 
research from other regions may reflect the high levels of discrimination and restricted health 
care access for transgender people in many countries worldwide.[58] 
Case reports, although considered to be low quality in the epidemiologic hierarchy 
(behind clinical trials, observational cohort studies and case control studies) and subject to bias, 
provided a  valuable tool to investigate uncommon postsurgical complications of a relatively rare 
surgery.[231, 232] As demonstrated by the 36 case reports, serious complications can occur 
decades after surgery - one woman presented with problems well over 4 decades after her 
vaginoplasty surgery.  
Among people who have intra-abdominal surgeries, most reported adverse effects 
occurred during hospitalization and usually very early in the postoperative period (within the 
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first 3 days).[233]  Transgender patients who have vaginoplasty surgery usually stay in the 
hospital for 5-7 days, thus most early complications should be captured by review of medical 
records. The published retrospective studies, predominately using chart review data, provided 
postsurgical follow up of patients for a range of 6 months to 13 years.  
Challenges with Measurement of Surgical Outcomes 
In the studies reviewed, reporting of adverse events was not uniform. Although some authors 
published comprehensive lists of complications with associated frequencies, others only 
provided a list but no rates of complications so that incidence of adverse outcomes could not be 
calculated. It also was unclear in many studies whether complications were listed by occurrence 
or by patient, i.e., how the authors captured the data if a person experienced a complication more 
than once. Many of the studies relied on review of medical records which may be incomplete and 
not adequately capture all variables. Although serious health issues, e.g., bleeding requiring 
transfusion, death and thromboembolic events are likely to be documented, less serious 
conditions may not be documented sufficiently, if at all.  
Postoperative outcomes were measured using multiple methodologies, making it difficult 
to compare these across studies or over time. Authors investigating aesthetics of the genitals after 
vaginoplasty at times used subjective measures such as documenting patient satisfaction,[110, 
112, 143] or attempted to apply objective measures, such as standardized physical examinations 
by the surgeon[108, 111] or scoring of photographs by professionals or lay people.[114] These 
last measures were possibly biased, especially with the surgeon or their colleagues grading the 
aesthetics of the surgeries they had performed. Vaginal depth for example could be measured 
subjectively by asking the patient if depth was sufficient[112, 117, 143] or by measuring with 
different sized dilators.[108, 113]  
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Psychosocial and Psychosexual Measures 
The ultimate goal of gender affirming surgeries is to align the body with a person’s gender 
identity and thereby to resolve gender dysphoria. Development of appropriate and validated 
psychosocial scales is an important tool to demonstrate efficacy of surgery to reduce gender 
dysphoria.  
In 1978 The University of Minnesota published methods to evaluate long-term outcomes 
for transgender women who had undergone vaginoplasty at their institution.[234] Each woman 
was to be her own control with monitoring of pre and post-surgery scores in 4 domains - 
economic, sexual and social outcomes. The highest “A” social score related to the ability of a 
person to blend into cisgender society, no longer having transgender friends, whereas a “D” 
score was for those engaging in “striptease dancing” with “multiple arrests by the morals squad” 
and “an undesirable ‘mess’”. This set the tone for outcome measures over the next decade.  
In this review there were few prospective studies that used objective psychosocial 
measures, especially in the earlier reports. Many were subjective and only allowed for yes/no 
categorical responses, e.g., whether the woman felt more feminine after surgery or if 
relationships with her family had improved. Some of the measures were vague such as ratings of 
“satisfaction with surgery” which could apply to either aesthetics or function. It was also unclear 
how some of the measures were related to surgery, for example the questions asking about job 
stability, marriage or arrest records. 
Some of the validated scales for sexual function developed for cis-populations have not 
been validated in transgender people, one example being the Female Sexual Function Index 
(FSFI).[222]  This index includes a score that assesses lubrication which is not physiologically 
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possible with split skin or penile inversion vaginoplasty, thereby artificially lowering scores. 
This and other scales may need to be appropriately tested and modified in transgender 
populations.  
Limitations 
As in any review, it is possible that some published literature was missed.  In addition, the 
review did not explore gray literature such as clinic or hospital reports or conference abstracts, 
all of which may have contributed important information. Although this review provides the first 
comprehensive summary of perioperative complications that have been attributed to vaginoplasty 
surgery, it is likely an under-estimate of the true number of complications, especially long-term 
adverse events. Transgender people may avoid health care due to previous instances of health 
care discrimination or anticipated stigma and may be less likely to seek preventive care, leading 
to delayed diagnoses.[39, 60]  
3.5 Conclusions and Recommendations 
In this scoping review to examine gender-affirming genital surgeries among transgender women, 
we identified over 100 research publications spanning a period of almost 4 decades, 
predominately from US and European based centers. Although there were multiple reports that 
addressed clinical outcomes and complications, many were low quality evidence, with over a 
third of the articles being case reports. There are currently few high-quality studies addressing 
the impact of these surgeries on general health and wellbeing. However, the review also 
demonstrated that in the last 5 years there has been an increase in studies using standardized and 
consistent outcome measures.  
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This review underscores the need for further research in this area. One recommendation 
would be to create registries for people undergoing these surgeries to improve tracking and valid 
measurement of clinical outcomes. Additionally, improved identification of transgender people 
in health care settings is needed since the current methods rely heavily on the use of diagnosis 
codes for gender identity disorder. The Williams Institute as well as other centers have advocated 
the use of the two-step question that asks about gender identity as well as sex assigned at 
birth.[66] This method has been validated to improve identification of transgender people.[65, 
235] Lastly there is a need for consistent and validated measures to evaluate short and long term 
outcomes after gender affirming surgeries. 
Since an increasing number of people are expressing an interest in gender-affirming 
surgery[60], it is important to provide clinicians with the resources and knowledge to deliver 
optimal and evidenced based care to transgender patients including those who access gender 
affirming interventions. 
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Chapter 4: Sexually Transmitted Infections among  
Transgender People 
4.1 Background 
Transgender people, i.e., individuals who have a gender identity that differs from the sex that 
they were assigned at birth are gaining more visibility in research and health settings.[6, 58] A 
recent meta-regression analysis indicated that approximately one million adults in the United 
States (US) aged 18 years and older  (0.4% of the adult population) identify as transgender[1] 
with an estimated 25 million adults worldwide. A higher proportion of youth, almost 2% of high 
school students, identify as transgender.[59] Although there are no US population-based 
estimates for the prevalence of gender nonbinary people, approximately 35% of the 27,715 
respondents of the 2015 U.S. Transgender Survey (USTS) identified as gender nonbinary.[60] 
Transgender women (“trans women” or “women of transgender experience”) are women 
who were assigned male at birth (i.e., born with male anatomy).  Transgender men (“trans men,” 
or “men of transgender experience”) are men who were assigned female at birth (i.e., born with 
female anatomy). Some individuals may identify outside the gender binary of male or female or 
move back and forth among different gender identities and use terms such as gender nonbinary, 
genderqueer, gender nonconforming or gender fluid to describe themselves. Agender or null-
gender persons do not identify with having any gender. The terms cisgender is used to describe 
persons who identify with their assigned sex at birth. 
Gender identity is independent from sexual orientation and sexual behavior. Transgender 
people might have sexual partners who are cisgender men, cisgender women, or other 
transgender or gender nonbinary people. Sexual orientation identities among transgender people 
          
75 
 
are diverse and in the USTS respondents predominately identified as queer (21%), pansexual 
(18%), gay/lesbian/same gender loving (16%), bisexual (14%) or asexual(10%).[60] 
Some transgender individuals may seek medical (hormonal and/or surgical) interventions 
in addition to social or legal changes, e.g., changing their name and/or gender marker.[6] The 
incidence of gender-affirming genital surgeries conducted in the U.S. has increased in the last 
decade.[92] 
Transgender people often experience high rates of stigma, socioeconomic and structural 
barriers to care that negatively impact healthcare utilization, increase susceptibility to human 
immunodeficiency virus (HIV) and sexually transmitted infections (STIs) and incur missed 
opportunities for HIV and STI prevention services.[9-16]. Transgender women carry elevated 
risk factors for HIV and other STIs including high rates of sex work (often exceeding 50%), 
condomless anal receptive sex, early sexual debut and high numbers of predominately cisgender 
men sexual partners. [17-23]. Although less is known about transgender men, studies have also 
demonstrated risk factors such as engaging in sex work, condomless sex with cisgender men and 
low rates of STI screening. [15, 34-37] 
A recent systematic review and metanalysis of HIV among transgender women estimates 
the US prevalence of HIV to be 14% among transgender women with the highest prevalence 
among black (44%) and Hispanic/Latino (26%) transgender women.[24] Data also suggest high 
rates of HIV among transgender women globally.[25] The few studies of HIV prevalence and 
incidence in transgender men suggest that they have a lower prevalence of HIV than transgender 
women, approximately 2%.[24]   
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Data on bacterial STIs among transgender women are limited due to the lack of 
widespread and consistent reporting of national surveillance data that includes gender-
identity.[236] Many studies reporting on STIs have therefore used clinic data or convenience 
samples. Despite limited data, international and US studies indicate elevated incidence and 
prevalence of rectal and pharyngeal (extragenital) Neisseria gonorrhoeae  (GC) and Chlamydia 
trachomatis (CT) infections among transgender women, similar to and frequently exceeding the 
rates seen among cisgender men who have sex with men (MSM).[23, 237-239] Other STIs, 
including syphilis, hepatitis B and C have also been reported among transgender women at high 
rates.[240-243]Among transgender men the highest STI risk occurs among those who have sex 
with cisgender men (known as trans MSM).[15] Transgender men have been found in a few 
small studies to have similar rates of GC, CT, hepatitis B and C compared to transgender 
women.[35, 244, 245] There are few data about the rates of STIs among gender nonbinary 
people. An evaluation of electronic health record data from 19 933 patients visiting a health 
center in Los Angeles, California found that STI positivity was 35% among gay and bisexual 
cisgender men, 25% among transgender women, 13% among gay and bisexual transgender men 
and 26% among nonbinary people.[246] Another study demonstrated elevated CT positivity in 
the last year among gender nonbinary people compared to cisgender men who have sex with men 
(MSM).[247] A recent high quality study using data from the Sexually Transmitted Disease 
(STD) Surveillance Network obtained STI prevalence among 506 transgender women and 120 
transgender men attending STD clinics in 25 jurisdictions across the U.S. Extragenital CT and 
GC infections were seen in 16.8% and 15% of transgender women and 14.3% and 12.1% of 
transgender men respectively. The rates of urogenital infections were 0.2%, 2.8% among 
transgender women and 4.1% and 7.1% among transgender men.[248] The proportions of 
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transgender people with extragenital chlamydia or gonorrhea infections were similar to those of 
cisgender MSM.[248]  It was not possible in this large study to investigate the incidence and 
prevalence of GC or CT infections in gender nonbinary people or in transgender people who had 
undergone genital surgery as data about nonbinary identities or surgeries were not documented.  
Most transgender women have not undergone genital gender-affirmation surgery and 
therefore still have a penis. They many engage in insertive oral, vaginal, or anal sex as well as 
receptive oral or anal sex. In the USTS 12% of transgender women had undergone vaginoplasty 
surgery and about half expressed an interest in having the surgery in the future.[60] The majority 
of vaginoplasty surgeries conducted in the US use penile and scrotal tissue to create the 
neovagina.[85, 249] Other surgical techniques use intestinal tissue (e.g., sigmoid colon graft) or 
split skin grafts.[88, 89] Although these surgeries involve penectomy (removal of the penis)  and 
orchiectomy (removal or testes), the prostate remains intact. Transgender women who have had a 
vaginoplasty might engage in receptive vaginal, oral or anal sex. Neovaginal STIs have 
infrequently been reported in the literature and include Herpes simplex infection of the neo-labia 
and human papilloma virus (HPV)/genital warts (in penile-inversion vaginoplasty) and Neisseria 
gonorrhoeae (in both penile-inversion and colo-vaginoplasty) of the neovagina.[170, 177, 182, 
198, 199, 250, 251] If the vaginoplasty used an intestinal graft there is additionally a risk, albeit 
rare, of bowel-related diseases such as inflammatory bowel disease, adenocarcinoma, diversion 
colitis and adenomatous polyps.[252-254]  
Transmasculine individuals may undergo genital gender affirmative surgeries, including 
construction of a neophallus (metoidioplasty or phalloplasty) and related surgeries including 
hysterectomy, oophorectomy, scrotoplasty and vaginectomy. The USTS indicated that the 
proportion of transgender men and non-binary individuals assigned female at birth who have 
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undergone gender affirmative genital surgery is low. Only 5% of transgender men had undergone 
phalloplasty or metoidioplasty; however, 44% planned to have it one day.[60] Many surgical 
options exist for transgender men and these are usually individualized to address the specific 
needs of each patient. For example, an individual can undergo a metoidioplasty (a procedure to 
increase the length of the clitoris), with or without urethral lengthening, and may or may not 
have a hysterectomy, oophorectomy or vaginectomy.[85, 255] Urethral lengthening is a 
procedure that involves creation of a competent urethra using buccal or vaginal mucosa and that 
allows persons to void while standing. The phalloplasty technique uses skin usually from the 
forearm, thigh, chest wall or abdomen to create a phallus. There are no published reports of 
sexually transmitted infections of the neophallus. 
There are limited data both about STI screening behaviors as well as STI prevalence 
among transgender people of all gender identities, including gender nonbinary people. To our 
knowledge, there are no data on these variables that are specific to people who have undergone 
genital surgeries. The aim of this report therefore is to examine rates of screening behaviors and 
prevalence of HIV, syphilis, GC and CT infections in transgender people using retrospective 
chart review data from a community health center in New York City (The Transgender Data 
Project). The prevalence of STIs and HIV are also compared among transgender men, 
transgender women and gender nonbinary people and rates of infections among those who have 
received GAHT or undergone gender affirming surgeries “medical gender-affirmation”.  
4.2 Methods 
Sample and Setting   
This study used data from the Callen-Lorde Community Health Center (CLCHC) and has been 
described in detail previously (Chapter 2). To summarize, this was a retrospective chart review 
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of transgender and gender nonbinary patients to answer questions about the health status of 
transgender clients ≥18 years old, using data gathered from the electronic health records between 
1/12009 and 12/31/2010.  
Subjects were registered patients 18 years of age or older treated at the CLCHC between 1/12009 
and 12/31/2010.  
Inclusion Criteria: 
1. A patient treated at the health center between 1/1/2009 and 12/31/2010 
2. Identified as transgender 
3. Age 18 or older 
4. No subject to be excluded from the study on the basis of gender, racial or ethnic origin.   
STI and HIV screening tests were determined from orders and results in the electronic health 
record. Hormone usage was determined from the medication lists. The social history template 
contained information on sexual partners, sex work and cigarette use. Medical diagnoses, e.g., 
substance use disorder, were available from ICD codes in the diagnosis template. Information 
was collected and stored in a password-protected electronic database.  The medical record 
numbers were de-identified to protect patient confidentiality. There was no key or linking list to 
allow matching of patient or patient identifiers to the database.  
This retrospective chart review (termed the Transgender Data Project on the application) 
obtained IRB approval from The Clinical Directors Network’s institutional review board on 
September 7, 2011. 
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Comparison with the New York City Community Health Survey 
The use of the New York City Community Health Survey (NYC CHS) as a comparison group 
was outlined in detail in Chapter 2. Every year the New York City Department of Health and 
Mental Hygiene conducts a community health survey (NYC CHS) of non-institutionalized adults 
who are 18 years and to better understand health care factors as well as risk behaviors. [62]  The 
NYC CHS was used to provide a comparison of HIV screening rates. As in chapter 2, NYC CHS 
participants who were engaged in care (could identify one or more primary care providers) were 
included in the analysis. The data set was merged with data from CLCHC allowing for a 
comparison of the proportions of people from both sources undergoing HIV screening 
Analysis 
The prevalence of the health conditions and screenings was calculated overall and also separately 
by birth-sex and age category. Pearson chi-square tests or Fisher’s exact tests for cell counts ≤5 
was used to compare categorical variables by birth sex and independent sample t-test to compare 
continuous variables by birth sex. Multivariable logistic regression models were used to assess 
the associations among gender identity and STI/HIV screening and gender identity and any STI 
or HIV positive diagnosis. All p-values are two-tailed at a significance level of 5%. Analyses 
were performed using IBM SPSS Statistics for Windows, Version 26.0 
4.3 Results 
A total of 3,197 records were initially retrieved. These were reviewed manually and 1670 of the 
records were identified as those of transgender patients. In 2010, CLCHC had 14,961 unique 
patients, therefore the prevalence of transgender patients at the center was 11.2%.  The 1670 
transgender people included 1093 who documented their assigned sex at birth as male, 577 who 
          
81 
 
documented their assigned sex at birth as female. Two intersex individuals were not included in 
subsequent analyses, Table 1






Table 1: Documentation of gender identity in electronic health records  
 Assigned Sex at Birth 
 Male Female Total 
Gender Identity n % n % n % 
Male 2 0.2 88 15.3 90 5.4 
Female 113 10.3 0 0 113 6.8 
Genderqueer 2 0.2 24 4.2 26 1.6 
FTM 0 0 14 2.4 14 0.8 
MTF 13 1.2 0 0 13 0.8 
Transgender 13 1.2 11 1.9 24 1.4 
Transgender female/woman 885 81.0 0 0 885 53.0 
Transgender male/man 0 0 413 71.6 413 24.7 
Transsexual 39 3.6 7 1.2 46 2.8 
Gender nonconforming 1 0.1 3 0.5 4 0.2 
Other 25 2.3 17 2.9 42 2.5 
Total 1093 100 577 100 1670 100 
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Demographics and Health Indicators 
The mean age of the sample was 35.57 years, SD 11.54, range 18.0-85.1). Transfeminine and 
transmasculine individuals differed significantly by age, race, education and employment. 
Transfeminine individuals were on average 37.4 years old (range: 18.0-85.1) while 
transmasculine individuals were approximately 5 years younger, p<.001. Transmasculine 
individuals were predominately white (55.0%) whereas transfeminine individuals were more 
likely to be people of color (71.3%), p<.001. The two populations differed in other ways, 
including rates of education. Transmasculine individuals were more highly educated with 95.1% 
having at least a high school diploma, 33.1% having a 4-year college degree and 18.7% holding 
a graduate degree compared to 84.1%, 17.7% and 6.6% among transfeminine individuals, 
p=<.001. Unemployment rates were much higher among transfeminine people – 28.7% among 
transmasculine and 46.4% among transfeminine people, p<.001. While both groups had similar 
rates of being uninsured (12.2% and 14.1%, p=.323) the types of insurance were different with 
transmasculine individuals twice as likely to have private insurance, p<.001. Transmasculine 
individuals were more likely to report stable housing vs. unstable/homeless 96.6% vs. 93.5%, 
p=.012, Table 2 
 
  













t-test (df) p-value (2-
sided) 












Race/Ethnicity % n=496 % n=942 % n=1438 χ2 (df) <.001 
Hispanic 11.7 58 29.4 277 23.3 335 114.38 (4) 
White 55.0 273 28.7 270 37.8 543 
Black 13.9 69 21.3 201 18.8 270 
Asian/Pacific 
Islander 
5.8 29 7.4 70 6.9 99 
Other 13.5 67 13.2 124 13.3 191 
Education 
(highest level) 
% n=493 % n=843 % n=1336 132.82 (4) <.001 
Less than High 
School 
4.9 24 15.9 134 11.8 158 
High School 
Diploma 
11.8 58 25.3 213 20.3 271 
Some College 31.6 156 34.5 291 33. 447 
Bachelors’ Degree 33.1 163 17.7 149 23.4 312 
Graduate degree 18.7 92 6.6 56 11.1 148 
Unemployment % n=540 % n=962 % n=1502 44.93 (1) <.001 
  28.7 155 46.4 446 40.0 601  
Housing (stable) % n=526 % n=939 % n=1465 6.25 (1) .012 
 96.6 508 93.5 878 94.6 1386  
Insurance % n=599 % n=944 % n=1443 147.60 (2) <.001 
Uninsured 12.2 61 14.1 133 13.4 194 
Private 60.5 302 28.6 270 39.6 572 
Public 27.3 136 57.3 541 46.9 677 
             
 
 
Sexual Partners  
Sexual health was first examined by investigating the sexual partners of transmasculine and 
transfeminine people as documented in the electronic health records, specifically whether their 
partners were cisgender or transgender men or women. The sexual partnerships in the study were 
diverse and individuals could have sex partners of more than one gender. Table 3 
Transmasculine individuals partnered most frequently with cisgender women (63.6%), 
followed by cisgender men (32.1%). Transgender women were slightly more likely to have sex 
partners that included cisgender men (64.3%) while 16.6% partnered with cisgender women, 
Table 5. Transfeminine individuals reported higher rates of sex work 5.5% vs. 0.3%, p<.001 
compared to transmasculine people. 
Table 3: Gender identity and gender of sex partner* 






Cisgender male  185 703 888 
Cisgender female  367 181 548 
Transgender male 18 6 24 
Transgender female 8 7 15 
None 52 122 174 
Missing 83 125 208 
*Not mutually exclusive 
 
HIV Screening and Prevalence 
Just over half of all transgender people in this study had undergone screening for HIV (55.7%). 
Rates of HIV screening among transfeminine individuals were higher (62.2% vs. 43.4%, p<.001) 
             
 
 
than for transmasculine individuals. HIV prevalence was 28.1% among transfeminine and 2.8% 
among transmasculine individuals (p<.001). Table 4 
Screening for Sexually Transmitted Infections 
Syphilis testing, using the rapid plasma reagin (RPR) test was done in fewer than half (44.8%) of 
transgender people and differed by gender identity. 40.1% of transmasculine and 47.3% of 
transfeminine individuals were screened (p=.005). No syphilis diagnoses occurred among 
transmasculine individuals however 5.6% of transfeminine people had a reactive RPR, p<.001. 
GC and CT testing occurred in 9.7% of transmasculine and 9.5% of transfeminine individuals 
(p=.800). There were no GC diagnoses among transmasculine individuals and only 1 case of CT 
(1.8%) whereas 4.9% of specimens tested positive for GC (p=.162) and 6.9% for CT among 
transfeminine individuals (p=.261). Genital warts were diagnosed in 2.8% of transmasculine and 
6% of transfeminine individuals, p<.001. Table 4 
  














t-test (df) p-value (2-
sided) 
Sex work % n=577 % n=1093 % n=1670 29.94 (1) <.001 
 0.3 2 5.5 60 3.7 62 
Substance use Disorder n=577 n=1093 n=1670 6.74 (1) .009 
 3.1 18 6.0 66 5.0 84 
HIV testing n=558 n=1055 n=1613 52.33 (1) <.001 
43.4 242 62.2 656 55.7 898 
Syphilis testing n=576 n=1092 n=1668 7.99 (1) .005 
 40.1 231 47.3 517 44.8 748   
Gonorrhea/chlamydia 
testing 
n=576 n=1092 n=1668 .064 (1) .800 
 9.7 56 9.3 102 9.5 158 
All STD testing n=576 n=1092 n=1668 7.99 (1) .005 
 40.3 238 49.1 536 46.4 774 9.14 (1) .002 
Sexually transmitted 
infections 
        
Gonorrhea n=56 n=102 n=158 2.84 (1) .162 
 0 0 4.9 5 3.2 5 
Chlamydia n=56 n=102 n=158 1.94 (1) .261 
 1.8 1 6.9 7 5.1 158 
Genital warts n=577 n=1093 n=1670 8.63 (1) 0.003 
 2.8 16 6.0 66 4.9 82 
Syphilis n=231 n=517 n=748 13.48 (1) <.001 
 0 0 5.6 29 3.9 29 
HIV n=250 n=672 n=922 69.82 (1) <.001 
 2.8 7 28.1 189 21.3 196 
Hormones  n=577 n=1093 n=1670 5.57 (1) .018 
 78.9 455 83.5 913 81.9 1368 
             
 
 
These data on HIV prevalence differed significantly by race. Among transfeminine 
individuals the prevalence was highest among people of color, 31.4% vs. 11.9%, p<.001. African 
American transfeminine individuals were three times as likely to be living with HIV with a 
prevalence of 45.6% compared to 21.2% among non-Black individuals (OR=3.12, 95% 
confidence interval: 2.06, 4.69; p<.001). Among transmasculine people HIV seroprevalence was 
3.2% among Hispanic, 6.8% among African American and 2.1% among white individuals, 
although these differences were not statistically significant (p= .597). Figure 1 
Figure 1: HIV Prevalence by Race/ethnicity 
 
 
Since the sexual transmission of HIV among transmasculine individuals is greater among those 
who identify as gay or bisexual and have sex with cisgender men, the prevalence of HIV was 
investigated by sex partner status. HIV seroprevalence was highest for those with cisgender male 
partners. The overall rate of HIV among transfeminine individuals was 28.1%, 29.8% among 
             
 
 
those with cisgender male partners only and 10% among those with cisgender female partners 
only (p=.003). The prevalence of HIV among transmasculine individuals who have sex 
exclusively with cisgender men was 11.1% vs. 2.1% in those who had sex exclusively with 
cisgender women. (p=.121).   The HIV seroprevalence was not statistically different between 
transmasculine and transfeminine individuals whose sex partners were exclusively cisgender 
men, p=.113, Table 5






Table 5: HIV status by gender identity and gender identity of sex partners 
 
†Reported p-values are from Fisher’s exact tests when cell sizes are less than 5
 Transmasculine Transfeminine All 
 
 
Sex partners n HIV
+ 
% n HIV+ % n HIV+ % χ2 (df) p-value† 
Any 250 7 2.8 672 189 28.1 922 196 21.3 69.82 
(1) 
<.001 
Cisgender male only 18 2 11.1 460 137 29.8 478 139 29.1 2.93 (1) .113 
Cisgender male + other 86 3 3.5 498 142 28.5 584 145 24.8 24.61 
(1) 
<.001 
Cisgender female only 94 2 2.1 50 5 10 144 7 4.9 4.37 (1) .049 
Cisgender female + 
other 
163 3 1.8 90 10 11.1 253 13 5.1 10.22 
(1) 
.002 
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Utilization of Gender-affirming Care 
The rates of gender affirming care including hormone therapy and surgeries were examined by 
gender identity. Eighty-two percent of all transgender people had accessed hormones, either 
testosterone for transmasculine or estrogens for transfeminine individuals. Transfeminine 
individuals were more likely to have accessed hormones, 83.5% vs. 78.9%, p=.018. 
Transmasculine surgical interventions included mastectomy, phalloplasty or 
metoidioplasty, hysterectomy and oophorectomy. Transfeminine surgeries included breast 
augmentation, orchiectomy, vaginoplasty and facial feminization surgery. Although these 
surgeries could not be directly compared, a variable for “any surgery” was created. 
Transmasculine individuals were more likely to undergo at least one gender affirming surgery 
(41.6% vs. 26.2%, p<.001) however transfeminine individuals were more likely to have received 
either hormones or surgery i.e., “any gender affirming intervention” (86% vs. 82%, p=.030). 
Table 6. One of the research questions was to investigate the prevalence of STIs among people 
who had undergone genital surgery. Transfeminine people who had undergone vaginoplasty 
were compared to those who had not.   The rate of genital warts was lower in those who had 
surgery (6.7% vs. 0%, p=.002) and there was also a statistically significant lower prevalence of 
HIV among those who had vaginoplasty (30% vs. 9.7%, p<.001). There was no association 
between STIs and orchiectomy only. Table 7 
Transmasculine individuals had a lower rate of genital surgeries and also low rates of 
STIs, therefore a meaningful comparison could not be made.  
  
            











Interventions N % Interventions N % χ2 (df) p-value 
Hormones 
(testosterone) 
455 78.9 Hormones 
(estrogens) 
913  83.5 5.57 (1) .018 
Mastectomy 227 39.3 Breast augmentation 167 15.3 - - 
Metoidioplasty 6  1.0 Orchiectomy 115  10.5 - - 
Phalloplasty 4  0.7 Vaginoplasty 103  9.4 - - 
Hysterectomy 53  9.2 Facial feminization surgery 98  9 - - 
oophorectomy 45 7.8    - - 
Any surgery  240  41.6 Any surgery 286  26.2 41.66 (1) <.001 
Any gender affirming 
intervention 
(hormones/surgery) 
473  82 Any gender affirming 
intervention 
(hormones/surgery) 
940 86 4.70 (1) .030 
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Table 7:  Vaginoplasty and STI prevalence 
 
†Reported p-values are from Fisher’s exact tests when cell sizes are less than 5









% χ2 (df) p-
value† 
Syphilis 28 5.8 1 2.9 .5337 (1) .711 
Genital warts 66 6.7 0 0 7.308 (1) .002 
Gonorrhea 5 5.2 0 0 .271 (1) 1.000 
Chlamydia 7 7.2 0 0 .387 (1) 1.000 
HIV 183 30 6 9.7 11.50 (1) <.001 
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Factors Associated with HIV Screening 
The HIV screening rate was 57%.  In the bivariate analysis for transmasculine individuals, the 
odds of HIV screening were lower for white individuals (OR=0.48, 95% CI=0.33, 0.69) and 
among those who were unemployed. There was a trend for increased screening in those who 
living in unstable housing however this was not significant, p=.601.  Receiving hormones 
(OR=1.64, 95% CI:1.06, 2.53) and gender affirming surgery (OR=1.46, 95% CI:1.04, 2.05) were 
both associated with increased odds of HIV screening. Other factors associated with HIV 
screening included having insurance (OR=1.89, 95% CI=1.06, 3.37), a history of genital warts 
(OR=5.92, 95% CI=1.67, 21.03) and substance use (OR=6.41,95% CI=1.82, 22.55). Age, race, 
insurance, hormones, gender affirming surgery, genital warts and substance use were entered in 
the multivariable analysis. After adjusting for all variables, non-white race, gender affirming 
surgery, substance use and genital warts were all positively associated with an increased odds of 
HIV screening. Table 8a 
For transfeminine individuals, non-white race, having a high school diploma, insurance, 
cisgender male partner, engaging in sex work, taking hormones, having a history of gender 
affirming surgery, substance use and genital warts were all associated with increased odds of 
HIV testing in the bivariate analysis. In the multivariate model analysis, cisgender male partner 
(OR=2.18, 95% CI= 1.52, 3.11), taking hormones (OR=2.56, 95% CI 1.53, 4.31), gender 
affirming surgery (OR=1.63, 95% CI=1.10, 2.41), substance use (OR=2.76, 95% CI=1.23, 5.78) 
and genital warts (OR=3.63, 95% CI=1.83, 7.20) were all associated with increased odds of HIV 
testing. Table 8b. 
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 Bivariate Multivariate 
 OR (95% CI) 
 
p-value OR (95% CI) 
 
p-value 
Age in years 1.02 (1.00, 1.04) .074 0.99 (0.97, 1.02) .500 
People of color   1.00  1.00  
White (non-Hispanic) 0.48 (0.33, 0.69) <.001 0.39 (0.26, 0.59) <.001 
Employed 1.00  -  
Unemployed 0.81 (0.55, 1.18) .275 -  
No high school diploma 1.00  -  
High school diploma 0.80 (0.35, 1.81) .586 -  
Uninsured 1.00  -  
Insured 1.89 (1.06, 3.37) .031 1.63 (0.83, 3.22) .160 
Stable home  1.00  -  
Unstable home 1.29 (0.50, 3.29) .601 -  
No cisgender male sex partner 1.00  -  
Cisgender male sex partner  0.94 (0.50, 1.76) .835 -  
No sex work 1.00  -  
Sex work 1.31 (0.08, 21.0) .850 -  
No chlamydia - - -  
Chlamydia - - -  
No hormones 1.00  1.00  
Hormones 1.64 (1.06, 2.53) .028 1.44 (0.79, 2.63) .232 
No gender affirming surgery 1.00  1.00  
Gender affirming surgery 1.46 (1.04, 2.05) .029 1.67 (1.08, 2.58) .022 
No substance use 1.00  1.00  
Substance use 6.41 (1.82, 22.55) .004 5.18 (1.41, 18.99) 0.013 
No syphilis - - -  
Syphilis - - -  
No Gonorrhea - - -  
Gonorrhea - - -  
No genital warts  1.00  1.00  
Genital warts 5.92 (1.67, 21.03) .006 4.64 (1.24, 17.34) .023 
No Silicone - - -  
Silicone - - -  
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 Bivariate Multivariate 
 OR (95% CI) 
 
p-value OR (95% CI) 
 
p-value 
Age in years 1.00 (0.99, 1.01) .669 1.01 (0.99, 1.02) .334 
People of color   1.00  1.00  
White (non-Hispanic) 0.45 (0.34, 0.61) <.001 0.51 (0.35, 0.75) .001 
Employed 1.00  -  
Unemployed 0.97 (0.74, 1.27) .849 -  
No high school 
diploma 
1.00  1.00  
High school diploma 0.66 (0.44, 1.00) .047 0.87 (0.52, 1.46) .605 
Uninsured 1.00  1.00  
Insured 1.63 (1.12, 2.37) .011 1.23 (0.76, 1.99) .403 
Stable home 1.00  -  
Unstable home 1.52 (0.85, 2.70) .159 , g-  
No cisgender male 
sex partner 
1.00  -  
Cisgender male sex 
partner only 
3.02 (2.33, 3.91) <.001 2.18 (1.52, 3.11) <.001 
No sex work 1.00  1.00  
Sex work 3.50 (1.70, 7.20) <.001 1.93 (0.77, 4.85) .164 
No chlamydia -  -  
Chlamydia -  -  
No hormones 1.00  1.00  
Hormones 2.24 (1.58, 3.19) <.001 2.56 (1.53, 4.31) <.001 
No gender affirming 
surgery 
1.00  1.00  
Gender affirming 
surgery 
1.59 (1.19, 2.12) .002 1.63 (1.10, 2.41) .014 
No substance use 1.00  1.00  
Substance use 3.23 (1.67, 6.24) <.001 2.76 (1.23, 5.78) .013 
No syphilis 1.00  -  
Syphilis 1.35 (0.54, 3.39) .523 -  
No Gonorrhea 1.00  -  
Gonorrhea 1.33 (0.14, 12.52) .801 -  
No genital warts  1.00  1.00  
Genital warts 3.63 (1.83, 7.20) <.001  2.69 (1.20, 6.02) .016 
No Silicone 1.00  -  
Silicone  1.68 (0.93,3.02) .084 -  
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HIV screening in the New York City Community Health Survey 
In 2011 the rate of ever having a test for HIV among participants in the NYC CHS who 
were engaged in care was 58.8% compared to 55.7% of transgender patients, p=.091. 
Factors Associated with HIV Status 
In the bivariate analysis for transmasculine individuals, HIV-positive status was associated with 
having a cisgender male partner (OR=5.68, 95% CI 1.02, 31.58). Individuals with at least a high 
school diploma had reduced odds of being HIV positive (OR=0.07, 95% CI=0.01, 0.49). Age, 
education and sex partner were placed into the multivariate model and both cisgender male 
partner (OR=10.58, 95% CI 1.33, 84.17) and high school diploma (OR 0.08, 95% CI 0.01, 0.72) 
remained a significant predictors of HIV status. Table 9a 
For transfeminine individuals the bivariate analysis demonstrated that non-white race, 
unemployment, having genital warts and a history of silicone use were significantly associated 
with HIV status. Vaginoplasty surgery (OR= 0.25; 95% CI=0.11, 0.59) and at least a high school 
diploma (OR= 0.44; 95% CI=0.28, 0.71) were associated with reduced odds of HIV infection. 
There was a trend to greater odds of HIV associated with sex work and syphilis infection, 
however these were not statistically significant. In the multivariate analysis unemployment (OR= 
1.71;95% CI=1.1, 2.64) a history of genital warts (OR=2.81; 95% CI=1.46, 5.41) were 
associated with greater odds of HIV infection and white race was associated with lower 
likelihood of infection (OR=0.40; 95% CI= 0.21, 0.73). Table 9b. 
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 Bivariate Multivariate 
 OR (95% CI) p-value OR (95% CI) p-value 
Age in years 1.00 (0.92, 1.09) .977  1.04 (0.93, 1.15) .522 
Non white  1.00  1.00  
White (non-Hispanic) 0.48 (0.09, 2.52) .383   
Employed 1.00  -  
Unemployed 2.19 (0.48, 10.06) .315 -  
No high school diploma 1.00  1.00  
High school diploma 0.07 (0.01, 0.49) .007 0.08 (0.01, 0.72) .009 
Stable home - - -  
Unstable home - - -  
Insurance - -   
No cisgender male sex partner 1.00  -  
Cisgender male sex partner only 5.68 (1.02, 31.58) .047 10.58 (1.33, 84.17) .026 
No sex work - - -  
Sex work - - -  
No chlamydia -  -  
Chlamydia - - -  
No hormones 1.00  -  
Hormones 1.08 (0.13, 9.21) .946 -  
No Gender affirming care 1.00  -  
Gender affirming care 0.78 (0.09, 6.73) .583 -  
No vaginoplasty N/A    
Vaginoplasty N/A    
No gender affirming surgery 1.00  -  
Gender affirming surgery 0.18 (0.02, 1.49) .111 -  
No substance use 1.00  -  
Substance use 2.73 (0.31, 24.23) .368 -  
No syphilis - - -  
Syphilis - - -  
No Gonorrhea - - -  
Gonorrhea - - -  
No genital warts  1.00  -  
Genital warts 3.21 (0.36, 28.81) .298 -  
No Silicone -  -  
Silicone - - -  
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 Bivariate Multivariate 
 OR (95% CI) p-value OR (95% CI) p-value 
Age in years 1.01 (1.00, 1.03) .189 1.02 (1.00, 1.04) .080 
Non white  1.00  1.00  
White (non-Hispanic) 0.30 (0.17, 0.52) <.001 0.40 (0.21, 0.73) .003 
Employed 1.00  1.00  
Unemployed 2.28 (1.58, 3.27) <.001 1.7 (1.1, 2.64) .016 
No high school diploma 1.00  1.00  
High school diploma 0.44 (0.28, 0.71) .001 0.64 (0.38, 1.10) .107 
Stable home 1.00  - - 
Unstable home 1.80 (0.95, 3.41) .072 - - 
Insurance     
No cisgender male sex partner 1.00 - - - 
Cisgender male sex partner only 1.31 (0.90, 1.89) .160 - - 
No sex work 1.00  -  
Sex work 1.79 (0.99, 3.23) .055 -  
No chlamydia 1.00  -  
Chlamydia 3.06 (.48, 19.57) .237 - - 
No hormones 1.00  - - 
Hormones 1.10 (0.62, 1.93) .749 - - 
No Gender affirming care 1.00  - - 
Gender affirming care 1.26 (.64, 2.47) .500 - - 
No vaginoplasty 1.00  1.00  
Vaginoplasty 0.25 (0.11, 0.59) .002 0.45 (0.17, 1.20) .109 
No gender affirming surgery 1.00  1.00  
Gender affirming surgery 0.82 (.56, 1.19) .292 - - 
No substance use 1.00  - - 
Substance use 1.35 (0.75, 2.41) .314 - - 
No syphilis 1.00  -  
Syphilis 2.20 (0.96, 5.04) .063 -  
No Gonorrhea 1.00  - - 
Gonorrhea 0.62 (0.06, 6.22) .681 - - 
No genital warts  1.00  1.00  
Genital warts 3.72 (2.16, 6.41) <.001 2.81 (1.46, 5.41) .002 
No Silicone 1.00  1.00  
Silicone 2.17 (1.17, 4.01) .013 1.65 (0.72, 3.77) .239 





The transfeminine and transmasculine individuals attending the Center differed in multiple ways. 
Transmasculine people were younger, predominately white, more highly educated, more likely to 
be employed and have stable housing when compared with transfeminine individuals.  
Gender Affirming Care 
Since some gender affirming procedures can directly impact sexual health and potentially risk of 
STIs and HIV, understanding the types of surgeries, especially genital surgeries, is essential to 
providing comprehensive sexual health services to transgender people. In this study uptake of 
gender affirming hormone therapy was found to be high in both groups, with 79% of 
transmasculine and 84% of transfeminine people using hormones. Fewer individuals had 
accessed gender affirming surgeries. In this report 26.2% of transfeminine individuals had 
accessed any gender affirming surgery compared to 41.6% of transmasculine individuals. The 
most common surgery for transmasculine people was bilateral mastectomy (39.3%) whereas the 
most common procedure for transfeminine individuals was breast augmentation (15.3%). The 
first US Transgender Discrimination Survey was published in 2011, around the same time as this 
retrospective chart review and included the experiences of 7500 transgender respondents across 
the USA. Similarly, about 80% of transgender women and 69% of transgender men had accessed 
hormone therapy. Approximately the same number of transgender men had accessed mastectomy 
(43%), but the rates of genital surgeries were much higher in the survey - metoidioplasty 4% and 
phalloplasty 2%. Twenty one percent of transgender women had undergone breast augmentation 
and 23% vaginoplasty, both higher than reported in this study.[39] It is likely that if this study 
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were repeated in 2019 that significantly higher numbers of people would have accessed gender-
affirming surgeries due to greater availability of surgeons as well as improved insurance 
coverage. 
HIV Screening Behavior 
Although HIV testing rates were low, they were similar to the rate seen in the 2011 NYC CHS. 
HIV testing was more likely to be undertaken by transfeminine individuals, 62% vs. 43%, 
p<.001.  A recent study published by the Centers for Disease Control and Prevention (CDC) 
revealed suboptimal HIV screening rates among 732 transgender women and 451 transgender 
men who participated in the Behavioral Risk Factor Surveillance System, an annual telephone 
survey of US adults. The HIV screening of 35.6% and 31.6% ever and approximately 10% in the 
last year was equivalent to screening rates among cisgender heterosexuals and far lower than the 
rates seen among cisgender MSM.[256]  The HIV screening rates were higher in this study, 
probably because all individuals were engaged in care and presumably had better access to HIV 
and STI care services. For transmasculine individuals. HIV testing was associated with receipt of 
gender affirming care (hormones and/or surgery), substance use and genital warts in the 
multivariable analysis.  HIV screening among transfeminine individuals was more likely to occur 
among non-white individuals (also seen in the CDC study), those with cisgender male partners, 
receipt of gender affirming hormones and surgery, substance use history and genital warts. 
The finding that gender affirming care was associated with increased screening is 
important. It may be because individuals engaged regularly in care (hormone care visits usually 
occur every 6 months) and therefore have more opportunities for testing, or it could be that 
individuals medically affirmed in their gender are more likely to engage in healthy screening 
behaviors. Before gender affirming surgery, many surgeons will require preoperative HIV 
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testing, which may explain the higher testing rate in the surgical group. Substance use and 
genital warts were associated with HIV screening. This could be due to more frequent 
interactions with medical providers and more opportunities to screen, or a perceived increased 
HIV risk and offers of screening by medical providers. Having cisgender male partners was 
associated with increased screening in transfeminine individuals only. It is not clear from these 
data if transmasculine individuals were offered and declined screening or if screening was never 
offered. Low rates of HIV screening among transmasculine individuals with cisgender male 
partners may be due to nondisclosure of sexual practices or that medical providers and patients 
are not aware of their elevated risk. 
HIV Prevalence 
This study revealed an elevated HIV prevalence of 28.1% among transfeminine individuals, 10 
times higher than among transmasculine individuals. The highest rates occurred in people of 
color, with a prevalence of 45.6% among those who identified as African American. Over the 
last 3 decades multiple studies have demonstrated a disproportionate risk of HIV among 
transgender women and supported the findings in this study.[19, 24, 257, 258] In the US, a 
recent metanalysis of 88 studies revealed a prevalence of 14.1% (95% CI = 8.7%, 22.2%) among 
transgender women but was much higher among Africans Americans at 44%.[24] This is also a 
serious health issue in international settings. A metanalysis that included data from 15 countries 
reported a pooled HIV prevalence of 19.1% (95% CI 17.4–20.7) in 11,066 transgender women 
worldwide.[25]  
There are fewer data regarding the prevalence of HIV among transgender men. A recent 
metanalysis that included only 7 small studies estimated prevalence to be 1.2% by self-report and 
3.2% laboratory confirmed.[24] There was no breakdown by race or ethnicity in these studies 
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due the small sample sizes. Data from the US National HIV Surveillance System describing the 
characteristics of the 2335 transgender people newly diagnosed with HIV between 2009 and 
2014 reported that over 58% of the 361 transgender men were African American.[259] These 
data are consistent with the findings in this report, that the highest prevalence occurred in 
African American transmasculine individuals (6.8%) followed by Hispanics (3.2%). 
Transmasculine individuals with at least a high school diploma had reduced odds of 
being HIV positive compared with those who had no high school diploma. Having cisgender 
male sex partners resulted in over a five-fold increase in the odds of HIV-infection.  Previous 
research has demonstrated that transgender men who have sex with cisgender men have higher 
rates of condomless sex, higher number of sex partners and substance use during sex, that 
probably contribute to elevated HIV prevalence in this population.[260] 
Increased odds of HIV infection among transfeminine individuals were associated with 
non-white race, unemployment and genital warts. An interesting finding was that vaginoplasty 
surgery was associated with a 75% reduced odds of HIV infection in the bivariate analysis but 
lost statistical significance in the multivariate analysis. The OR, although suggestive of a 
protective effect from vaginoplasty is possibly related to the fact that surgeons often refused to 
do these procedures in women living with HIV. The association of HIV with genital warts can be 
explained by both being sexually transmitted as well as human papilloma virus (HPV) infections 
being more prevalent and persistent in people with HIV, rather than to an etiologic factor. HPV 
is also frequently isolated from transgender women who have sex with men.[261] It is possible 
that infection with HPV may be a proxy for increased number of sex partners.   
 




There were many limitations to this study, the first being that these were all patients engaged in 
care at a single community health center that is recognized for their transgender health program. 
It is likely that these patients were not representative of the transgender adult population in the 
USA. Although there were two trained chart reviewers, it is possible that data were entered 
incorrectly or that patients were misclassified. Although an analysis to compare binary and 
nonbinary identified people was planned, the data were sparse, necessitating collapsing of 
categories into transmasculine and transfeminine which may have obscured important 
differences between these groups.  
Additional challenges were missing data and incomplete records; in many situations the 
notes were incomplete and important information of HIV and STI risk factors were missing. It 
was also not possible to confirm whether data were current, e.g., for insurance data, housing 
status etc.  
There was an extremely low rate of STI screening and very low STI prevalence. The low 
rate of STIs may have been low due to suboptimal screening practices and/or because the testing 
that was available did not use nucleic acid amplification testing for gonorrhea testing and instead 
used culture, which is not as sensitive for detection of gonorrhea. 
Lastly, the data used in this analysis came from a chart review done over 9 years ago and 
it is possible that trends in health care uptake may have changed due to greater accessibility of 
insurance and health settings willing to provider gender affirming care. The study is still relevant 
however due to the fact that there have few studies published during this time examining primary 
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care outcomes, none examining colon cancer screening and none assessing HIV prevalence for 
transmasculine individuals who exclusively have sex with cisgender men, 
4.5 Conclusion 
This study of the health care utilization of transgender people was the largest to date conducted 
at a community clinic in the US. The findings were consistent with many previous observations, 
such as elevated HIV risk among transfeminine individuals, especially transgender women of 
color. This current study adds new information by stratifying HIV prevalence among transgender 
people by the gender of sexual partners. The highest risk occurred among transfeminine 
individuals who had cisgender male sexual partners (29.8%) and the lowest rates occurred 
among those with cisgender female partners (10%).  This was also reported among 
transmasculine people, with an overall prevalence of 2.8% that increased to 11.1% among those 
who had sex exclusively with cisgender men. This is important because the current belief is that 
transmasculine people have little risk and therefore often are not targeted for HIV prevention 
interventions. This has important implications for researchers and policy makers who have 
frequently not addressed HIV vulnerability among transmasculine individuals.  
HIV screening has been found to be suboptimal in transgender populations. The finding 
in this study that screening rates are highest in those receiving gender affirming care suggests 
that this could be investigated further as part of expanding HIV prevention efforts. 
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Chapter 5: Dissertation Summary and Conclusions 
 
The aim of this dissertation was to add to the body of knowledge about the state of health of 
transgender individuals, in particular to describe the utilization of gender affirming medical care 
(gender affirming hormone therapy and surgeries) and uptake of preventive healthcare among 
transgender patients. Three studies were conducted. The first was a retrospective chart review 
that described the characteristics of transgender people in care, the types of gender affirming 
procedures they accessed and an investigation of preventive care quality measures, specifically 
colorectal cancer screening using colonoscopy and cigarette smoking that were compared to New 
York City benchmarks found in the New York City Community Health Survey. The second 
study was a scoping review of the literature to examine the types of vaginoplasty procedures and 
associated postoperative complications that can occur, both immediate and long term. The final 
study was an investigation of HIV and STI screening practices among transgender people that 
provided predictors of HIV screening and prevalence. 
Summary of Results 
Chapter Two, the first study, used data obtained from a retrospective chart review of transgender 
patients in care at a New York City community health center. The purpose was to describe 
utilization of gender affirming care by transgender patients. In order to do this an algorithm was 
developed to identity transgender patients that used a combination of ICD codes, medication 
history and discordant names and gender markers. Once the database was established further 
analyses could be run to examine the uptake of health care services, transition-related and 
otherwise.   In this chapter, the diversity of gender identities held by transgender people was 
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highlighted as well as significant differences in baseline characteristics, uptake of gender 
affirming care and preventive care by transmasculine and transfeminine people  
Transmasculine people were younger, predominately white, more highly educated, more 
likely to be employed and have stable housing compared with transfeminine individuals. Uptake 
of gender affirming hormone therapy was high in both groups, with 79% of transmasculine and 
84% of transfeminine people using hormones however fewer individuals had accessed gender 
affirming surgeries; 26.2% of transfeminine individuals compared to 41.6% of transmasculine 
individuals, p<.001. Of particular concern was that when compared to predominately cisgender 
participants in the New York City Community Health Survey, Transgender people had a higher 
likelihood of smoking (OR=1.92; 95% CI=1.61, 2.28) and transgender individuals 50 years and 
older were far less likely to undergo colonoscopy, OR=0.16; 95% CI=0.11, 0.23.  
This report underscores the need for data about transgender people to be disaggregated by 
gender identity and not combined as a single “transgender” population in research studies. This 
study also brings to light a significant disparity in colon cancer screening and supports previous 
research finding a higher prevalence of cigarette smoking in transgender populations.  
Chapter three described the second study, a scoping review of vaginoplasty surgery in 
transgender women to investigate short and long-term health outcomes related to these surgeries. 
Gender-affirming genital surgeries are not common and primary care providers and other 
healthcare workers are likely to be unfamiliar with these procedures and how to provide adequate 
postoperative follow-up. One hundred and three articles met the inclusion criteria and revealed 
that despite an increase in the number of studies published over time, many were low quality 
descriptive studies and there were no uniform measures of outcomes, which ranged from 
postsurgical complications to measures of function, esthetics and quality of life. Thirty-six of the 
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studies were case reports that demonstrated that serious complications can occur decades after 
surgery - one woman presented with problems well over 4 decades after her vaginoplasty 
procedure. There is a need to develop standardized outcomes that can be replicated across 
studies. 
Chapter 4 described the third study in the dissertation which had the aim to describe the 
prevalence of HIV and sexually transmitted infections (STIs) among transgender clients 
attending a New York City Health Center and to investigate HIV and STI screening practices. 
The hypothesis was that there would be distinct differences in the prevalence of HIV and STIs 
between transgender men and transgender women and more importantly to add to the sparse data 
regarding HIV risk in transmasculine individuals. Several important findings were seen. Firstly, 
the study supported what is currently know about HIV in transfeminine individuals, showing 
HIV prevalence of 28.1%, with highest rates among those who identified as African American 
(45.6%). Among transmasculine individuals the HIV prevalence of 2.8% was within the range 
previously reported in the literature. What was new was the ability to show that HIV prevalence 
was higher among those with cisgender male partners only, 11.1%. Transmasculine individuals 
with cisgender male partners were almost 11 times more likely to be HIV-positive, OR=10.58; 
95% CI 1.33, 84.17). Another key point was the association of gender affirming surgeries with 
HIV and STI prevalence. One of the research questions was to investigate the prevalence of STIs 
among people who had undergone genital surgery. Transfeminine people who had undergone 
vaginoplasty were compared to those who had not.  The rate of genital warts was lower in those 
who had surgery (6.7% vs. 0%, p=.002) and there was also a statistically significant lower 
prevalence of HIV among those who had vaginoplasty (30% vs. 9.7%, p<.001). Having gender 
affirming surgery was also associated with improved HIV screening rates for both 
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transmasculine (OR=1.67;95% CI=1.08, 2.58) and transfeminine individuals (OR=1.63;95% 
CI=1.10, 2.41). Although the association between surgeries and lower HIV/STI prevalence and 
improved screening maybe a marker of better engagement in care and surgical restrictions, it 
raises the possibility that access to gender affirming procedures improves other health outcomes. 
Strengths and Limitations 
The analysis of this dissertation provided some key strengths. Firstly, data on 1670 transgender 
people makes it one of the largest single site studies on transgender health in the USA. In 
addition, as the site was a federally qualified health community health center in an urban area, 
the population was more racially and ethnically diverse than seen in similar studies done in 
Europe.  
There were many limitations to with this dissertation, the first being external validity. 
The data used for the studies in Chapter 2 and 4 were from a single center, albeit a center serving 
the largest number of transgender patients in the country. It is highly likely that these patients 
were not representative of the transgender adult population in the USA, or even other 
transgender people in New York. The patients in care at CLCHC had access care regardless of 
ability to pay, and were readily prescribed hormones. This experience alone is unlikely to be 
replicated nationally. 
Although there were two trained chart reviewers, it is possible that data were entered 
incorrectly or that patients were misclassified. Many of the data points, especially for substance 
use were incomplete. Unfortunately, there were insufficient data on mood disorders, such as 
anxiety and depression, so these could not be included in the analyses that investigated primary 
care outcomes and HIV/STI risk.  
            
110 
 
It was not possible in these studies to disaggregate the separate outcomes of nonbinary 
identified people as the data were sparse. This led to the collapsing of categories into 
transmasculine and transfeminine which may have obscured important differences between these 
groups. When reviewing the possible reasons for the invisibility of nonbinary identities it became 
clear that this was one area where the timing of the study (the chart review was mostly covered 
information from 2010) could have impacted disclosure of identity. Guidelines in use at the time 
restricted gender affirming surgeries to transgender people with binary identities. It is likely that 
some non-binary identified people stated they were trans men or women in order to access these 
gender-affirming procedures. 
There was an extremely low rate of STI screening and very low STI prevalence. The low 
rate of STIs may have been low due to low screening prevalence and/or because the testing that 
was available did not include nucleic acid amplification testing for gonorrhea. It was not possible 
to compare STI screening among cisgender individuals or with NYC benchmarks as this was not 
a question that was included in the NYC CHS. It was not possibly to investigate any aspect of 
STIs in transmasculine people due to this extremely low prevalence. 
There were important variables that were not collected during the chart review, such as 
mental health diagnoses, psychotherapeutic interventions and social support. These can all 
impact on HIV and STI risk and would have improved interpretation on results.  
Lastly, the data used in this analysis came from a chart review done over 9 years ago and 
it is possible that trends in health care uptake may have changed due to greater accessibility of 
insurance and health settings willing to provider gender affirming care. The study is still relevant 
however due to the fact that there have no few studies published during this time examining 
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preventive care and there are still large gaps in knowledge about HIV and STI risk among 
transmasculine individuals. 
Public Health Implications 
There are several public health implications resulting from this dissertation. The first issue, and 
possibly most important, is that in order to investigate health outcomes among transgender 
people, gender identity needs to be uniformly collected, not only in electronic health records 
(EHRs) but also in large data sets and national health surveys, such as The National Health and 
Nutrition Examination Survey (NHANES) and The National Health Interview Survey (NHIS).  
 Second, public health programming, especially for HIV and STI prevention, should focus 
efforts on risk and not just gender identity. Currently most of the HIV prevention efforts for 
transgender people have been for transgender women however this dissertation has shown that 
transmasculine individuals who have sex with cisgender men, have a 10-fold greater prevalence 
of HIV compared with those without cisgender male partners, and need to be prioritized in HIV 
prevention programming, including behavioral and biomedical interventions, such as HIV pre-
exposure prophylaxis.  
Future Research Agenda 
This dissertation highlighted many areas that still need to be studied and the need to create a 
comprehensive research agenda for transgender and gender non-binary people.  
Further research needs to be done to investigate health outcomes in transgender 
populations. There have been recent attempts to create cohort studies of transgender people, 
including Trans Pop, the first US national probability sample of transgender individuals (www. 
http://www.transpop.org/). These efforts need to continue. Other possibilities for creating large 
datasets include pooling of data from multiple clinics. This will require better methods to identity 
            
112 
 
transgender people in EHRs, since currently centers capture data on gender identity and birth sex 
differently, depending on the capability of their systems.  
This dissertation revealed that receipt of medical gender-affirmation may influence 
promotion of healthy behaviors, such as HIV screening. Future research should be undertaken to 
understand the effect of gender-affirming interventions on health outcomes as well as to 
understand the pathways by which this may occur, e.g., through mediation of stigma. 
The strategy used in this paper uncovered the fact that misclassification of birth sex 
occurred in about 6% of transgender patients.  Further research needs to be done to understand 
whether transgender patients who conceal their birth identity experience different health care 
outcomes compared to those who disclose their birth sex. 
The scoping review of vaginoplasty surgeries revealed that little has been done to create 
outcomes that have been validated for use in transgender populations. With more and more 
surgeries being done, it is vital to validate surgical outcome measures as well as to investigate 
the association of gender affirming care with other non-transition related health outcomes.  
To conclude, this dissertation has brought new research findings to the field of transgender 
medicine and has highlighted research gaps that can be explored in future studies. 
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